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ABSTRACT

The invention provides a series of novel Lipid A analogs that
are structually simple, synthetically accessible, and capable
of blocking the cellular receptor within the signal transduc
tion pathway. The novel Lipid A analogs can include a
monosaccharide core with hydrophobic side chains and
amino acid ionic motif. The invention further provides meth
ods of using the compounds and compositions thereof in
various therapeutic methods.
19 Claims, 4 Drawing Sheets
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SACCHARDE CONUGATES
RELATED APPLICATIONS

This application is a National Stage Application of PCT/
US2012/034064, filed on Apr. 18, 2012, which claims prior
ity to U.S. Provisional Patent Application No. 61/517,380,
filed Apr. 18, 2011, and which applications are incorporated
herein by reference.
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GOVERNMENT SUPPORT

This invention was made with government Support under
Grant No. 1R15AG033913-01 awarded by the National Insti
tutes of Health. The United States Government has certain

2
derivative was inactive gave rise to a belief that the omission
of at least one phosphate results in a complete loss of activity
(Rossignol et al., Endotoxin in Health and Disease, eds.
Brade, Opal, Vogel and Morrison, Marcel Dekker, Inc., New
York Basel, 1999, pp. 699-717: Christ et al., J. Am. Chem.
Soc., 1994, 116, 3637-3634).
Accordingly, there is a need for compounds that antagonize
LPS signaling without activating the inflammatory cascade.
There is also a need for Lipid A analogs that lack the com
plexity of the highly lipidated diphosphorylated disaccharide
core yet still maintain potent antagonistic activity against
LPS.

15

SUMMARY

rights in the invention.
BACKGROUND OF THE INVENTION

Septicemia is a serious world-wide health problem associ
ated with mortality rates of 40-60%. It has been estimated that
1% of hospital patients and 20-30% of ICU patients develop
sepsis. The cardiovascular consequences of septic shock
resulting from bacterial infections include myocardial dys
function that develops in nearly all patients, vascular tone and
permeability abnormalities, as well as abnormal oxygen
delivery and metabolism. As a result, vital organs such as the
brain, heart, kidneys, and liver may be affected or may fail,
and this reflects in over 100 000 deaths annually in the US.
Septic shock is initiated by the introduction of a bacterial
endotoxin (or lipopolysaccharide, LPS) into the blood
stream. LPS (FIG. 1), a vital component of the outer leaflet of
the gram-negative outer membrane, has been shown to be a
principle mediator of the depression of left ventricular func
tion and myocardial contractility.
LPS is comprised of three structural regions. One of these,
the Lipid A region, consists of a polyacylated glucosamine
disaccharide and is largely responsible for the toxic activity.
The results of recent studies Suggest that the ensuing proin
flammatory response to LPS is by far more dangerous than the
mere presence of LPS in circulation. LPS exerts its effects via
interaction with a plasma LPS-binding protein (LBP), which
has strong affinity for both the LipidA region of the endotoxin
and glycosylphosphatidyl inositol-anchored LPS receptor
CD14 on mononuclear phagocytes. The LPS-LBP complex
then interacts with CD14 followed by further complex for
mation with Toll-like receptor 4 (TLR4) and its co-receptor
MD-2. TLR4 is an integral membrane protein that transmits
the LPS signal to the inside of the cell and initiates the sig
naling pathways that lead to production of proinflammatory
molecules. Such as the cytokine, tumor necrosis factor C.
(TNFC).
Recent advances in the understanding of LPS structure
function relationships have provided some clues on the struc
tural determinants responsible for the endotoxic activity of
Lipid A. These determinants include the number and chain
length of fatty acids (lipids), the disaccharide core, and the
1,4'-diphosphate groups of the E. coli type (1, FIG. 1). The
fair stability (chemical or in vitro) of this class of compounds
has been a major drawback in their synthesis and application.
Although the exact role of the phosphate moieties is still
unknown, the observation that a 1-hydroxyl-4'-O-phosphate

25

The invention provides compounds, such as lipopolysac
charide antagonists, that can have various biological and
medical applications. For example, a new and structurally
simplified series of Lipid A analogs is described. The Lipid A
analogs can be carbohydrate conjugate and can include a
carboxyl moiety and highly lipophilic chains. The inventive
lipid A analogs, such as the monosaccharide-amino acid con
jugates, can include a monosaccharide core with hydrophobic
side chains and amino acid ionic motif.

Accordingly, the invention provides a compound of For
30

mula I:

(I)

OR3
35

R2O
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RO
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O

40

is.us x1 R
O

wherein
45

R" is (C-C)alkyl:
R and Rare each independently (Cs-C)alkyl: (Cs-C)
alkenyl; or (Cs-C)alkanoyl;

R" is H. (C-C)alkyl, or aryl;
50

n is 0-9:

L is a methylene, a linking group or a direct bond;
X is O, S, or N:
55

60

65

R is an oxygen-linked, Sulfur-linked, or nitrogen-linked
amino acid that is optionally protected on oxygen or nitrogen
with an oxygen or nitrogen protecting group, or that is option
ally Substituted on a nitrogen of the amino acid with one, two,
or three alkyl groups (e.g., thereby forming an alkylated
amino group or a quaternary ammonium group on the nitro
gen);
wherein any alkyl, alkenyl, alkanoyl or aryl is optionally
Substituted with one or more substituents, such as hydroxy,
oXo, alkyl, alkoxy, alkylcarbonyl, alkylcarbonyloxy, nitro,
halo, trifluoromethyl, trifluoromethoxy, cyano, or amino
groups, or a combination thereof;
or a pharmaceutically acceptable salt or Solvate thereof.

US 9,120,838 B2
4
The invention also provides novel compounds of the for
mulas described herein, intermediates for the synthesis of
compounds of the formulas described herein, as well as meth
ods of preparing compounds of the formulas described
herein. The invention also provides compounds of the formu

3
The invention also provides compounds of Formula II:
(II)
OR3

las described herein that are useful as intermediates for the

R2O

synthesis of other useful compounds. The invention provides
for the use of compounds of F the formulas described herein

OH

for the manufacture of medicaments useful for the treatment
OH

10

of inflammation and/or bacterial infections in a mammal,
Such as a human.

wherein n is 0, 1, 2, or 3; P is a nitrogen protecting group; or
a pharmaceutically acceptable salt or Solvate thereof, where
the remaining variables are as defined for Formula I. The
amino group of Formula II (the N(H) (P) group) can also be
alkylated to form a dialkyl amine, or a trialkyl ammonium
group, which can then include any pharmaceutically accept

15

The invention yet further provides for the use of the com
pounds and compositions described herein for use in medical
therapy. The medical therapy can be treating inflammation,
sepsis, or endotoxemia. The invention also provides for the
use of a composition as described herein for the manufacture
of a medicament to treat the aforementioned conditions. The

medicament can include a pharmaceutically acceptable dilu
ent, excipient, or carrier.
BRIEF DESCRIPTION OF THE DRAWINGS

able counterion.

The invention also provides compounds of Formula III:

The following drawings form part of the specification and
are included to further demonstrate certain embodiments or

(III)

O
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H1NP

OMe

or a pharmaceutically acceptable salt or Solvate thereof,

invention.
35

wherein R. R. and P are as defined for Formula II. The
amino group of Formula III (the —N(H) (P) group) can also
be alkylated to form a dialkyl amine, or a trialkyl ammonium
group, which can then include any pharmaceutically accept
able counterion.

Any of the compounds described herein can be combined
with a a pharmaceutical carrier, diluent, or excipient to pro
vide a pharmaceutical composition. The composition can be
formulated, for example, for intraperitoneal injection or infu

40

45

sion to a mammal.

The invention also provides methods for treating or inhib
iting the deleterious effects of endotoxemia or septic shock.
The methods can include administering to a Subject afflicted
with endotoxemia or septic shock an effective amount of a
compound or composition described herein wherein the del
eterious effects of endotoxemia are thereby treated or inhib
ited. The deleterious effects of endotoxemia or septic shock
can be one or more of a reduction in white blood cells, a high
respiratory rate, an elevated heart rate, an elevated tempera
ture, or multiple organ failure.
The invention further provides methods for blocking or
inhibiting the signal transduction pathway that leads to sepsis.
The method can include administering to a subject afflicted
with, or having an increased risk of being afflicted with,
sepsis, an effective amount of a compound or composition
described herein wherein the signal transduction pathway
that leads to sepsis is blocked or inhibited.
The invention also provides compounds that block a cellu
lar receptor within a signal transduction pathway. The meth
ods can include using the compounds to block the signal
transduction pathway that leads to sepsis.

various aspects of the invention. In some instances, embodi
ments of the invention can be best understood by referring to
the accompanying drawings in combination with the detailed
description presented herein. The description and accompa
nying drawings may highlight a certain specific example, or a
certain aspect of the invention. However, one skilled in the art
will understand that portions of the example or aspect may be
used in combination with other examples or aspects of the

50

FIG.1. Structures of the Lipid A region of E. coli LPS (1)
and known structural mimetics thereof (2-5). Compound 2
was reported by Boons et al. (J. Am. Chem. Soc., 2003, 125,
6103–61 12). Compound 3 was reported by Shiozaki et al.
(Tetrahedron, 2006, 62. 205-225). Compounds 4 and 5 were
reported by Peri et al. (Angew. Chem., Int. Ed., 2007, 46.
3308-3312).
FIG. 2. Compounds 10, 12, and 13 do not display LPS
antagonistic activity. THP-1 human monocytes were treated
as described in Example 2 with 10 ng/mL PMA for 24hat 37°
C. and 5% CO. The medium was then removed and adherent
macrophages were further treated as described with increas
ing concentrations of compounds 10 (panel A), 12 (panel B)
and 13 (panel C) for 30 min followed incubation with 10
ng/mL LPS for 6h. Secreted TNFC. was measured by ELISA
and the levels (ng/mL) were reported on the y-axis after
normalization by the number of counted macrophages (cells/
mL). Error bars represent the standard error (std. err.) for 3
different TNFC. measurements from each cell treatment.
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FIG. 3. Compound 11 displays LPS antagonistic activity
and cell toxicity. THP-1 macrophages were treated as
described in the FIG. 2 legend with increasing concentrations
of compound 11. Secreted TNFC. levels (circles) are the aver
age +/-std. err. for n=2 trials and are reported as the %
response of LPS in the absence of antagonist compound
Immediately following the cell treatment described above
and in FIG. 2 legend, macrophage viability (triangles) (n=2
trials) was determined by XTT reduction as described in
Example 2. Cell viability is presented as a percentage of the
cell viability measured in the absence of antagonists.
FIG. 4. Compound 19 displays highly potent LPS antago
nistic activity. THP-1 macrophages were treated in 3 separate
experiments as described in the FIG.2 legend with increasing
concentrations of compound 19. Secreted TNFC. levels were

US 9,120,838 B2
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determined in the presence (circles) (n=9 trials) and absence
(diamonds) (n=6 trials) of LPS. Cell viability (triangles) (n=9
trials) was also assessed and presented as described in the
FIG.3 legend.
FIG. 5. Compound 24 displays significant LPS antagonis
tic activity without toxicity. THP-1 macrophages were treated
in 4 separate experiments as described in the FIG. 2 legend
with increasing concentrations of compound 24. Secreted
TNFC. levels were determined in the presence (circles) (n=12
trials) and absence (diamonds) (n=8 trials) of LPS. Cell
viability (triangles) (n=12 trials) was also assessed and pre
sented as described in the FIG. 3 legend.
FIG. 6. LPS antagonistic activity displayed by compound
4. THP-1 macrophages were treated in 3 separate experi
ments as described in the FIG. 2 legend with increasing con
centrations of compound 4. Secreted TNFC. levels were deter
mined in the presence (circles) (n=8 trials) and absence
(diamonds) (n=5 trials) of LPS. Cell viability (triangles)
(n=11 trials) was also assessed and presented as described in
the FIG. 3 legend.

6
ingly found that compounds that included various moieties
Such as a methylglucoside monosaccharide core, one or more
hydrophobic chains to facilitate membrane intercalation, and
an amino acid to provide an ionic character, were able to
provide potent antagonistic activity. An efficient synthesis of
conjugates of this type, and biological studies of their endot
oxic activity in vitro, is described herein.
DEFINITIONS
10

15

densed Chemical Dictionary 14" Ed., by R. J. Lewis, John

Wiley & Sons, New York, N.Y., 2001.
References in the specification to “one embodiment”, “an
embodiment', etc., indicate that the embodiment described

DETAILED DESCRIPTION

Sepsis is a serious medical condition characterized by bac
terial infection and a Subsequent massive systemic inflamma
tory response. The release of proinflammatory products and
mediators from responding innate immune cells, such as
mononuclear phagocytes, directly contributes to the patho
genesis of sepsis. The primary bacterial trigger of inflamma
tion is lipopolysaccharide (LPS), which interacts with the
germline-encoded macrophage receptor cluster of differen
tiation 14 (CD14) via its Lipid A moiety. In an effort to
identify compounds that block LPS-induced inflammation, a
series of Lipid A analogs that lack a disaccharide core yet still
possess potent antagonistic activity against LPS were inves
tigated. Compounds containing the following moieties were
developed: a glucopyranoside core, hydrophobic ether Sub
stituents, and an amino acid to provide an ionic character to
the constructs. An efficient synthesis of these compounds and
the ensuing biological studies thereof are described herein.
To develop molecules that antagonize LPS signaling with
out activating the inflammatory cascade, simplified Lipid A
analogs that lack the complexity of the highly lipidated
diphosphorylated disaccharide core yet still maintain potent
antagonistic activity against LPS were developed. The Syn
thesis, and unprecedented LPS-antagonistic activity, of Vari
ous methyl glucopyranoside-amino acid conjugates is
described below. This project was inspired by published
reports of compounds that are structurally dissimilar to Lipid
A yet still exhibit potent antagonistic activity. Amongst a
myriad of research articles that have been disseminated in the
past years, the following three noteworthy discoveries pro
vided background for the new developments.
First, as reported by Boons etal. (J. Am. Chem. Soc., 2003,
125, 6103–61 12), a strong binding and antagonistic effect was
achieved even with phosphateless Rhizobium syn-1 disac
charide 2, which bears a lactone moiety at the reducing end
(FIG. 1). Second, Shiozaki et al. (Tetrahedron, 2006, 62.
205-225) showed that a strong anti-LPS antagonistic
response can be achieved, even with disaccharide 3, in which
the non-reducing glucosamine is replaced with glucose.
Third, Pen et al. (Angew. Chem., Int. Ed., 2007, 46, 3308
3312) demonstrated that methyl glycoside-heterocycle con
jugates 4 and 5 provide antagonistic activity. In view of these
structural dissimilarities from E. coli LPS, the development
molecules that contain the new structural variations, while

maintaining antagonistic activity, was sought. It was Surpris

As used herein, the recited terms have the following mean
ings. All other terms and phrases used in this specification
have their ordinary meanings as one of skill in the art would
understand. Such ordinary meanings may be obtained by
reference to technical dictionaries, such as Hawley's Con

25

30

35

may include a particular aspect, feature, structure, moiety, or
characteristic, but not every embodiment necessarily includes
that aspect, feature, structure, moiety, or characteristic. More
over, such phrases may, but do not necessarily, refer to the
same embodiment referred to in other portions of the speci
fication. Further, when a particular aspect, feature, structure,
moiety, or characteristic is described in connection with an
embodiment, it is within the knowledge of one skilled in the
art to affect or connect Such aspect, feature, structure, moiety,
or characteristic with other embodiments, whether or not

explicitly described.
The singular forms “a,” “an and “the include plural
reference unless the context clearly dictates otherwise. Thus,
for example, a reference to “a compound includes a plurality
of such compounds, so that a compound Xincludes a plurality
of compounds X. It is further noted that the claims may be
drafted to exclude any optional element. As such, this state
ment is intended to serve as antecedent basis for the use of

40

exclusive terminology, such as “solely,” “only, and the like,
in connection with the recitation of claim elements or use of

a “negative' limitation.
The term “and/or” means any one of the items, any com
bination of the items, or all of the items with which this term
45

is associated. The phrase “one or more' is readily understood
by one of skill in the art, particularly when read in context of
its usage. For example, one or more substituents on a phenyl
ring refers to one to five, or one to four, for example if the
phenyl ring is disubstituted.

50

The term “about can refer to a variation of +5%, +10%,

55

+20%, or +25% of the value specified. For example, “about
50 percent can in some embodiments carry a variation from
45 to 55 percent. For integer ranges, the term “about can
include one or two integers greater than and/or less than a
recited integer at each end of the range. Unless indicated
otherwise herein, the term “about is intended to include

60

65

values, e.g., weight percents, proximate to the recited range
that are equivalent in terms of the functionality of the indi
vidual ingredient, the composition, or the embodiment.
As will be understood by the skilled artisan, all numbers,
including those expressing quantities of ingredients, proper
ties such as molecular weight, reaction conditions, and so
forth, are approximations and are understood as being option
ally modified in all instances by the term “about.” These
values can vary depending upon the desired properties sought
to be obtained by those skilled in the art utilizing the teachings
of the descriptions herein. It is also understood that such

US 9,120,838 B2
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values inherently contain variability necessarily resulting
from the standard deviations found in their respective testing
measurementS.

As will be understood by one skilled in the art, for any and
all purposes, particularly in terms of providing a written
description, all ranges recited herein also encompass any and
all possible Sub-ranges and combinations of Sub-ranges
thereof, as well as the individual values making up the range,
particularly integer values. A recited range (e.g., weight per
cents or carbon groups) includes each specific value, integer,
decimal, or identity within the range. Any listed range can be
easily recognized as Sufficiently describing and enabling the
same range being broken down into at least equal halves,
thirds, quarters, fifths, or tenths. As a non-limiting example,
each range discussed herein can be readily broken down into
a lower third, middle third and upper third, etc. As will also be
understood by one skilled in the art, all language such as “up
to”, “at least”, “greater than”, “less than”, “more than”, “or

10

15

2 to about 24 carbon atoms, 2 to 10 carbon atoms, 2 to 6

25

30

35

40

cals and substituents. Generic terms include each of their

species, and in other embodiments, can exclude one or more
of their species. For example, the term halo includes and can
explicitly be fluoro, chloro, bromo, or iodo.
The term “alkyl refers to a branched, unbranched, or
cyclic hydrocarbon having, for example, from 1-30 carbon

45

atoms, and often 1-12, 1-10, 1-8, 1-6, or 1-4 carbon atoms.

50

Examples include, but are not limited to, methyl, ethyl, 1-pro
pyl, 2-propyl(iso-propyl), 1-butyl, 2-methyl-1-propyl(isobu
tyl), 2-butyl (sec-butyl), 2-methyl-2-propyl(t-butyl), 1-pen
tyl, 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl,
3-methyl-1-butyl, 2-methyl-1-butyl, 1-hexyl, 2-hexyl,
3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2pentyl, 3-methyl-3-pentyl, 2-methyl-3-penty1, 2,3-dimethyl
2-butyl, 3.3-dimethyl-2-butyl, hexyl, octyl, decyl, dodecyl
tetradecyl, octadecyl, and the like. The alkyl can be unsubsti
tuted or optionally substituted, for example, with one or more
substituents described below. In some embodiments, the alkyl
can also be optionally partially or fully unsaturated. As such,
the recitation of an alkyl group can optionally include both
alkenyl or alkynyl groups, in certain embodiments. The alkyl
can be a monovalent hydrocarbon radical, as described and
exemplified above, or it can be a divalent hydrocarbon radical
(i.e., an alkylene), depending on the context of its use.

sp' double bond) having about 2 to about 30 carbon atoms in

a chain. In some embodiments, the alkenyl group can include

more', and the like, include the number recited and such

terms refer to ranges that can be subsequently broken down
into Sub-ranges as discussed above. In the same manner, all
ratios recited herein also include all sub-ratios falling within
the broader ratio. Accordingly, specific values recited for
radicals, Substituents, and ranges, are for illustration only;
they do not exclude other defined values or other values
within defined ranges for radicals and Substituents.
One skilled in the art will also readily recognize that where
members are grouped together in a common manner, such as
in a Markush group, the invention encompasses not only the
entire group listed as a whole, but each member of the group
individually and all possible subgroups of the main group.
Additionally, for all purposes, the invention encompasses not
only the main group, but also the main group absent one or
more of the group members. The invention therefore envis
ages the explicit exclusion of any one or more of members of
a recited group. Accordingly, provisos may apply to any of the
disclosed categories or embodiments whereby any one or
more of the recited elements, species, or embodiments, may
be excluded from Such categories or embodiments, for
example, as used in an explicit negative limitation.
Specific values listed below for radicals, substituents, and
ranges, are for illustration only; they do not exclude other
defined values or other values within defined ranges for radi

8
For example, the alkyl group can be substituted with one or
more alkyl group Substituents that can be the same or differ
ent, where the “alkyl group substituent can be an alkyl, halo,
arylamino, acyl, hydroxyl, aryloxy, alkoxyl, alkylthio.
arylthio, aralkyloxy, aralkylthio, carboxy, alkoxycarbonyl,
OXO or cycloalkyl. There can be optionally inserted along the
alkyl chain one or more oxygen, Sulfur or Substituted nitrogen
atoms, wherein the nitrogen Substituent is hydrogen, lower
alkyl (thereby forming an “alkylaminoalkyl), or aryl.
"Branched alkyl groups can be an alkyl group in which a
lower alkyl group. Such as methyl, ethyl or propyl, is attached
to linear alkyl chain.
The term “alkenyl refers to a partially unsaturated alkyl
group (i.e. an alkyl that includes at least one carbon-carbon,
carbon atoms, or 2 to 4 carbon atoms. Examples include, but
are not limited to, ethylene or vinyl, allyl, cyclopentenyl, and
5-hexenyl. The alkenyl can be unsubstituted or substituted,
for example, by one or more alkyl groups or other Substituents
described below. The alkenyl can be a substituent (monoradi
cal) or an internal group (an alkenylene). The alkenyl group
can be straight, branched or cyclic. The alkenyl group can be
also optionally unsaturated and/or Substituted with one or
more “alkyl group substituents”. There can be optionally
inserted along the alkenyl group one or more oxygen, Sulfur
or Substituted nitrogen atoms, wherein the nitrogen Substitu
ent is alkyl as previously described.
The term “cycloalkyl refers to cyclic alkyl groups of for
example, from 3 to 10 carbon atoms having a single cyclic
ring or multiple condensed rings. Cycloalkyl groups include,
by way of example, single ring structures Such as cyclopro
pyl, cyclobutyl, cyclopentyl, cyclooctyl, and the like, or mul
tiple ring structures such as adamantyl, and the like. The
cycloalkyl group can be monovalent or divalent, and can be
optionally Substituted, for example, by one or more alkyl
groups or other substituents described below. The cycloalkyl
group can optionally include one or more cites of unsatura
tion, for example, the cycloalkyl group can include one or
more carbon-carbon double bonds, such as, for example,
1-cyclopent-1-enyl, 1-cyclopent-2-enyl, 1-cyclopent-3-enyl,
cyclohexyl, 1-cyclohex-1-enyl, 1-cyclohex-2-enyl, 1-cyclo
hex-3-enyl, and the like. There can be optionally inserted
along the cyclic alkyl chain one or more oxygen, Sulfur or
Substituted nitrogen atoms, wherein the nitrogen Substituent
is hydrogen, lower alkyl, or aryl, thus providing a heterocy
clic group.
The term “aryl refers to an aromatic hydrocarbon group
derived from the removal of at least one hydrogen atom from
a single carbon atom of a parent aromatic ring system. The
radical attachment site can be at a Saturated or unsaturated
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carbon atom of the parent ring system. The aryl group can
have from 6 to 20 carbon atoms, for example, about 6-10
carbonatoms, in the cyclic skeleton. The aryl group can have
a single ring (e.g., phenyl) or multiple condensed (fused)
rings, wherein at least one ring is aromatic (e.g., naphthyl,
dihydrophenanthrenyl, fluorenyl, or anthryl). Typical aryl
groups include, but are not limited to, radicals derived from
benzene, naphthalene, anthracene, biphenyl, and the like. The
aryl can be unsubstituted or optionally substituted, as
described for alkyl groups. The aromatic rings of the aryl
group may each and optionally contain heteroatoms. The aryl
group can be optionally Substituted with one or more aryl
group substituents that can be the same or different, where
“aryl group Substituent can include an alkyl, aryl, arylalkyl
(e.g., benzyl), hydroxy, alkoxyl, aryloxy, arylalkoxyl, car

US 9,120,838 B2
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boxy, acyl, halo, nitro, alkoxycarbonyl, aryloxycarbonyl, ary
lalkoxycarbonyl, acyloxyl, acylamino, aroylamino, carbam
oyl, alkylcarbamoyl, dialkylcarbamoyl, arylthio, alkylthio.
alkenyl or —NRR' group, where Rand R' can each indepen
dently be hydrogen, alkyl, aryl or arylalkyl.
The term “substituted indicates that one or more (e.g., 1,

cal residues of an amino acid include its amino residue and its

2, 3, 4, or 5; in some embodiments 1, 2, or 3; and in other

embodiments 1 or 2) hydrogenatoms on the group indicated
in the expression using “substituted” is replaced with a “sub
stituent”. The substituent can be one of a selection of the

indicated group(s), or it can be a suitable group known to
those of skill in the art, provided that the substituted atoms
normal valency is not exceeded, and that the Substitution
results in a stable compound. Suitable Substituent groups
include, e.g., alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl,
hydroxy, hydroxyalkyl, aryl, aroyl, heteroaryl, heterocycle,
cycloalkyl, alkanoyl, alkoxycarbonyl, amino, alkylamino,
dialkylamino, trifluoromethylthio, difluoromethyl, acy
lamino, nitro, trifluoromethyl, trifluoromethoxy, carboxy,
carboxyalkyl, keto, thioxo, alkylthio, alkylsulfinyl, alkylsul
fonyl, arylsulfinyl, arylsulfonyl, heteroarylsulfinyl, heteroar
ylsulfonyl, heterocyclesulfinyl, heterocyclesulfonyl, phos
phate, Sulfate, hydroxyl amine, hydroxyl(alkyl)amine, or
cyano. Additionally, Suitable Substituent groups can be, for

10

vitro, or in vivo.
An “effective amount” refers to an amount effective to treat
15

25

—S(=O).OH, -S(=O).R, OS(=O),OR, S(=O)
NR, -S(=O)R,
OP(=O)(OR), -P(=O)(OR),
—P(=O)(O) = P(=O)(OH), C(=O)R, C(=O)x,
C(S)R, C(O)CR, C(O)O, C(S)OR, C(O)SR,
C(S)SR, C(O)NRR, C(S)NRR, or C(NR)NRR,
where each X is independently a halogen (“halo'): F, Cl, Br,
or I; and each R is independently H, alkyl, aryl, (aryl)alkyl
(e.g., benzyl), heteroaryl, (heteroaryl)alkyl, heterocycle, het
erocycle(alkyl), or a protecting group. As would be readily
understood by one skilled in the art, when a substituent is keto
(=O) or thioxo (=S), or the like, then two hydrogen atoms
on the Substituted atom are replaced. In some embodiments,
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one or more of the substituents above are excluded from the

group of potential values for substituents on the substituted
group.

The term “solvate” refers to a solid compound that has one
or more solvent molecules associated with its Solid structure.

carboxylic acid residue. Appropriate residues can often be
condensed to form linkages. For example, an amino residue
and a carboxylic acid residue can be condensed to form a
peptide bond. A typical residue of a saccharide includes any
one of its hydroxyl groups, and in several embodiments, the
anomeric hydroxyl.
The term “contacting refers to the act of touching, making
contact, or of bringing to immediate or close proximity,
including at the cellular or molecular level, for example, to
bring about a physiological reaction, a chemical reaction, or a
physical change, e.g., in a solution, in a reaction mixture, in

45

Solvates can form when a solid compound is crystallized

a disease, disorder, and/or condition, or to bring about a
recited effect. For example, an amount effective can be an
amount effective to reduce the progression or severity of the
condition or symptoms being treated. Determination of a
therapeutically effective amount is well within the capacity of
persons skilled in the art. The term “effective amount” is
intended to include an amount of a compound described
herein, or an amount of a combination of compounds
described herein, e.g., that is effective to treat or prevent a
disease or disorder, or to treat the symptoms of the disease or
disorder, in a host. Thus, an “effective amount generally
means an amount that provides the desired effect.
The terms “treating”, “treat' and “treatment” include (i)
preventing a disease, pathologic or medical condition from
occurring (e.g., prophylaxis); (ii) inhibiting the disease,
pathologic or medical condition or arresting its development;
(iii) relieving the disease, pathologic or medical condition;
and/or (iv) diminishing symptoms associated with the dis
ease, pathologic or medical condition. Thus, the terms
“treat”, “treatment, and “treating extend to prophylaxis and
include prevent, prevention, preventing, lowering, stopping
or reversing the progression or severity of the condition or
symptoms being treated. As such, the term “treatment'
includes both medical, therapeutic, and/or prophylactic
administration, as appropriate.
The terms “inhibit”, “inhibiting, and “inhibition” refer to
the slowing, halting, or reversing the growth or progression of
a disease, infection, condition, or group of cells. The inhibi
tion can be greater than about 20%, 40%, 60%, 80%, 90%,
95%, or 99%, for example, compared to the growth or pro
gression that occurs in the absence of the treatment or con
tacting.

from a solvent, wherein one or more solvent molecules

The term “endotoxemia' refers to a blood condition where

become an integral part of the solid crystalline matrix. The
compounds of the formulas described herein can be solvates,
for example, ethanol Solvates. Another type of a Solvate is a
hydrate. A “hydrate' likewise refers to a solid compound that
has one or more water molecules intimately associated with
its solid or crystalline structure at the molecular level. A
hydrate is a specific type of a Solvate. Hydrates can form when
a compound is solidified or crystallized in water, wherein one
or more water molecules become an integral part of the Solid
crystalline matrix. The compounds of the formulas described
herein can be hydrates.
The term “residue' refers to an atom or group of atoms that
are part of a larger molecule. For example, while an amino
acid is a compound, one can refer to an amino acid residue as
the compound linked to another molecule through a covalent
bond. Such as by the formal removal of a hydrogen from an
amino terminus, a carboxy terminus, or from a side chain of

endotoxins are present in the blood, leading to inflammation.
When the endotoxins are derived from gram-negative (and/or
rod-shaped) bacteria, their presence can cause hemorrhages,
necrosis of the kidneys, and septic shock.
The term "septic shock” refers to a condition resulting
from severe infection and sepsis, where the infection can be
local or systemic. In humans, septic shock has a specific
definition requiring several conditions to be met for diagno
sis. First, SIRS (systemic inflammatory response syndrome)
must be diagnosed by finding at least any two of the follow
ing: a) tachypnea (high respiratory rate) >20 breaths per
minute, or on blood gas, a PCO less than 32 mmHg signify
ing hyperventilation; b) white blood cell count either signifi

the amino acid, to form a direct bond with the other molecule.

A residue can also refer to a portion of a molecule used to link
one molecule to another molecule to form a conjugate. Typi
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cantly low, <4000 cells/mm or elevated >12000 cells/mm:
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c) heart rate >90 beats per minute; and d) high temperature:
fever >38.5° C. (101.3°F) or hypothermia <35.0° C. (95.0°
F.). Second, there must be sepsis. Sepsis requires evidence of
infection, which may include positive blood culture, signs of
pneumonia on chest X-ray, or other radiologic or laboratory
evidence of infection. Third, signs of end-organ dysfunction

US 9,120,838 B2
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are required Such as renal failure, liver dysfunction, changes
in mental status, or elevated serum lactate. Finally, septic
shock is diagnosed if there is refractory hypotension (low
blood pressure that does not respond to treatment). This sig

12
silyl, and diphenylmethylsilyl. Some specific protecting
groups that can be employed in conjunction with the methods
of the invention are discussed below.

nifies that intravenous fluid administration alone is insuffi

cient to maintain a patient’s blood pressure from becoming
hypotensive.
Septic shock resulting from gram-negative bacterial infec
tions is initiated by movement of bacterial endotoxin (LPS)
into the blood stream. LPS is a vital component of the outer
leaflet of the gram-negative outer membrane. It is comprised
of three structural units, among which a Lipid-A region con
sisting of a polyacylated glucosamine disaccharide is largely
responsible for the toxic activity of LPS. Evidence of a proin
flammatory response to LPS is more important than detection

10

15

of LPS in circulation. The effects of LPS are initiated after it

interacts with a plasma LPS-binding protein (LPB). LPB has
a strong affinity for the Lipid-A portion of endotoxin, as well
as or glycophosphatidyl inositol-anchored LPS receptor
CD14 on mononuclear phagocytes. When a LPS-LPB com
plex interacts with CD14 (and then TLR-4), the cells produce
a variety of proinflammatory factors, such as TNFC. The
compounds described herein can inhibit the production of
Such proinflammatory factors.
Protecting Groups
The term “protecting group' refers to any group that, when
bound to a hydroxyl, nitrogen, or other heteroatom, prevents
undesired reactions from occurring at the sight of the heteroa
tom, and which group can be removed by conventional
chemical or enzymatic steps to reestablish the unprotected
hydroxyl. nitrogen, or other heteroatom group. The particular
removable group employed is often interchangeable with
other groups in various synthetic routes. Certain removable
protecting groups include conventional Substituents such as,
for example, allyl, benzyl, acetyl, chloroacetyl, thiobenzyl,
benzylidine, phenacyl, methyl methoxy, silyl ethers (e.g.,
trimethylsilyl (TMS), t-butyl-diphenylsilyl (TBDPS), or
t-butyldimethylsilyl (TBS)) and any other group that can be
introduced chemically onto a hydroxyl functionality and later
selectively removed either by chemicalorenzymatic methods
in mild conditions compatible with the nature of the product.
A large number of protecting groups and corresponding
chemical cleavage reactions are described in Protective
Groups in Organic Synthesis, Theodora W. Greene (John
Wiley & Sons, Inc., New York, 1991, ISBN 0-471-62301-6)
(“Greene', which is incorporated herein by reference in its
entirety). Greene describes many nitrogen protecting groups,
for example, amide-forming groups. In particular, see Chap
ter 1, Protecting Groups: An Overview, pages 1-20, Chapter
2, Hydroxyl Protecting Groups, pages 21-94, Chapter 4, Car
boxyl Protecting Groups, pages 118-154, Chapter 5, Carbo
nyl Protecting Groups, pages 155-184, and Chapter 7, Pro
tection for the Amino Group. See also Kocienski, Philip J.;
Protecting Groups (Georg Thieme Verlag Stuttgart, New
York, 1994), which is incorporated herein by reference in its
entirety, and D. Voet, Biochemistry, Wiley: New York, 1990;
L. Stryer, Biochemistry, (3rd Ed.), W. H. Freeman and Co.:
New York, 1975; and J. March, Advanced Organic Chemistry,
Reactions, Mechanisms and Structure, (2nd Ed.), McGraw
Hill: New York, 1977: F. Carey and R. Sundberg, Advanced
Organic Chemistry, Part B. Reactions and Synthesis, (2nd
Ed.), Plenum: New York, 1977; and references cited therein,
for various protecting group manipulations and other syn
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Isomers

As to any of compound described herein, which contains
50

55
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thetic transformations.

Specific useful protecting groups include benzyl, acetyl,
trifluoroacetyl, benzoyl, benzyloxycarbonyl, Fmoc, and sili
con protecting groups such as trimethylsilyl, t-butyldimetyl

Typical nitrogen protecting groups described in Greene
(pages 14-118) include benzyl ethers, silyl ethers, esters
including Sulfonic acid esters, carbonates, Sulfates, and Sul
fonates. For example, Suitable nitrogen protecting groups
include substituted methyl ethers; substituted ethyl ethers:
p-chlorophenyl, p-methoxyphenyl, 2,4-dinitrophenyl, ben
Zyl; substituted benzyl ethers (p-methoxybenzyl, 3,4dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, p-haloben
Zyl. 2,6-dichlorobenzyl, p-cyanobenzyl, p-phenylbenzyl, 2
and 4-picolyl, diphenylmethyl, 5-dibenzosuberyl, triphenyl
methyl, p-methoxyphenyl-diphenylmethyl, di(p-methox
yphenyl)phenylmethyl, tri(p-methoxyphenyl)methyl, 1.3benzodithiolan-2-yl, benzisothiazolyl S.S.-dioxido); silyl
ethers (silyloxy groups) (trimethylsilyl, triethylsilyl, triiso
propylsilyl, dimethylisopropylsilyl, diethylisopropylsilyl,
dimethylthexylsilyl, t-butyldimethylsilyl, t-butyldiphenylsi
lyl, tribenzylsilyl, tri-p-xylylsilyl, triphenylsilyl, diphenylm
ethylsilyl, t-butylmethoxy-phenylsilyl); esters (formate, ben
Zoylformate, acetate, choroacetate, dichloroacetate,
trichloroacetate, trifluoroacetate, methoxyacetate, triphenyl
methoxyacetate, phenoxyacetate, p-chlorophenoxyacetate,
3-phenylpropionate, 4-oxopentanoate (levulinate), pivaloate,
adamantoate, crotonate, 4-methoxycrotonate, benzoate,
p-phenylbenzoate, 2,4,6-trimethylbenzoate (mesitoate)); car
bonates (methyl, 9-fluorenylmethyl, ethyl, 2.2.2-trichloroet
hyl, 2-(trimethylsilyl)ethyl, 2-(phenylsulfonyl)ethyl,
2-(triphenylphosphonio)ethyl, isobutyl, vinyl, allyl, p-nitro
phenyl, benzyl, p-methoxybenzyl, 3,4-dimethoxybenzyl,
o-nitrobenzyl, p-nitrobenzyl, S-benzyl thiocarbonate,
4-ethoxy-1-naphthyl, methyl dithiocarbonate); groups with
assisted cleavage (2-iodobenzoate, 4-azidobutyrate, 4-nitro
4-methylpentanoate, o-(dibromomethyl)benzoate, 2-formyl
benzenesulfonate, 2-(methylthiomethoxy)ethyl carbonate,
4-(methylthiomethoxy)butyrate, miscellaneous esters (2,6dichloro-4-methylphenoxyacetate, 2,6-dichloro-4-(1.1.3.3
tetramethylbutyl)phenoxyacetate, 2.4-bis(1,1-dimethylpro
pyl)phenoxyacetate, chlorodiphenylacetate, isobutyrate,
monosuccinate,
(E)-2-methyl-2-butenoate(tigloate),
o-(methoxycarbonyl)benzoate, p-poly-benzoate, C.-naph
thoate, nitrate, alkyl N,N,N',N'-tetramethyl-phosphorodiami
date, n-phenylcarbamate, borate, 2,4-dinitrophenyl
Sulfenate); and Sulfonates (sulfate, methanesulfonate
(mesylate), benzylsulfonate, tosylate, triflate).
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one or more Substituents, it is understood, of course, that Such

groups do not contain any Substitution or Substitution patterns
that are sterically impractical and/or synthetically non-fea
sible. The total molecular weight of substituents on a single
group will typically be less than about 600, 500, 400, 300,
200, or 100. It will be appreciated that the compounds of the
invention can contain asymmetrically Substituted carbon
atoms, and may be isolated in optically active or racemic
forms. It is well known in the art how to prepare optically
active forms, such as by resolution of racemic forms or by
synthesis from optically active starting materials or by the use
of enantioselective catalytic reactions. All chiral, diastereo
meric, racemic forms and all geometric isomeric forms of a
compound are intended as part of this invention.
Throughout the specification and claims, a given chemical
formula or name not having a specific designation shall
encompass all optical and stereoisomers as well as racemic
mixtures where such isomers and mixtures exist.

US 9,120,838 B2
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One diastereomer may display Superior activity compared
to another. When required, separation of racemic materials
can be achieved by high performance liquid chromatography
(HPLC) using a chiral column or by a resolution using a
resolving agent Such as camphonic chloride, as in Thomas J.
Tucker et al., J. Med. Chem. 1994, 37, 2437-2444. A chiral

compound may also be directly synthesized using a chiral
catalyst or a chiral ligand; see, for example, Mark A. Huffman
et al., J. Org. Chem. 1995, 60, 1590-1594.
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COMPOUNDS OF THE INVENTION
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(I)
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RO

R
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The saccharide side chains R and R can be a variety of
such, the R and R groups can each independently be fatty
acid moieties (e.g., linked to the formula through the oxygen
on the R or R group, wherein the fatty acid moiety refers to
the carboxyl group of the fatty acid which is bonded to the
oxygen on the R or R group). The fatty acid moiety can be
medium to long-chain alkyl, alkenyl, or alkanoyl groups. As

A compound of Formula I:

R2O

14
Suitable monosaccharides include glucuronic acid, Sorbase,
ribose, and the like. A saccharide can include hydroxyl pro
tecting groups such as, but not limited to, acetyl groups,
benzyl groups, benzylidene groups, silyl groups, methoxy
ether groups, or combinations thereof. The Saccharide groups
can also be in pyranose form, furanose form, or linear form.
Depending on the context, as would be understood by one of
skill in the art, the saccharide can include the oxygen that
links it to another group, or exclude the oxygen that links it to
another group.

x1

O
25

wherein

R" is (C-C)alkyl;
R and Rare each independently (Cs-C)alkyl: (Cs-C)

alkenyl; or (Cs-Cal)alkanoyl, optionally substituted or inter
rupted, including where the alkyl, alkenyl, or alkanoyl is one
of various fatty acid moieties;

30

R" is H. (C-C)alkyl, or aryl:
n is 0-9:

L is a methylene, a linking group or a direct bond;
X is O, S, or N:

R is an oxygen-linked, Sulfur-linked, or nitrogen-linked
amino acid that is optionally protected on oxygen or nitrogen
with an oxygen or nitrogen protecting group;
wherein any alkyl, alkenyl, alkanoyl or aryl is optionally
Substituted with one or more hydroxy, oxo, alkyl, alkoxy,
alkylcarbonyl, alkylcarbonyloxy, nitro, halo, trifluoromethyl,
trifluoromethoxy, cyano, or amino groups;
or a pharmaceutically acceptable salt or Solvate thereof.

Specific values for R' include methyl, ethyl, and propyl.
Specific values for RandR include any one or more of the

35
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of the R or R group can also be, for example, optionally

epoxidized, optionally substituted with one or more hydroxyl
groups, optionally substituted with one or more oxo groups,
optionally interrupted by one or more oxygenatoms (thereby
forming ether or ester groups), or a combination thereof.
Other fatty acid chains can be prepared by Standard starting
materials and reaction conditions such as those described by
Kunau (Synthesis of unsaturated fatty acids, Chem. Phys.
Lipids 1973, 11, 254-269), Rembold et al. (Synthesis of Kdo
O-glycosides of lipid A derivatives, Carbohydr. Res. 1993,
246, 137-159), and Dixon et al. (The total synthesis of the
anonaceous acetogenin, muricatetrocin C, Angew. Chem. Int.

Ed. 2000,39,3622-3626). In certain embodiments, one of R

and R can be H.
45

saccharide fatty acid substituents described or illustrated
herein.

The linker L can be a methylene, a direct bond, or a divalent
radical “linking group of the formula—W-A-W wherein
W is N(R')C(=O) , —C(=O)N(R') , OC(=O) ,
—C(=O)C) , O—, S—, S(O) , S(O) ,
—N(R')— —C(=O)—, or absent; wherein each R" is inde
pendently H. (C-C)alkyl, or a nitrogen protecting group;
and A can be (C-C)alkyl, (C-C)alkenyl, (C-C)alky
nyl, (C-C)cycloalkyl, (C-Co.)aryl, —(OCH CH)—
where n is 1 to about 20, —C(O)NH(CH), wherein n is 1 to
about 6, OP(O)(OH)O - OP(O)(OH)O(CH), wherein
n is 1 to about 6, OP(O)(OH)OCHCH(OH)CH-, - N'
(Me)(CH), wherein n is 1 to about 6, or (C-Co.)alkyl,
(C-C)alkenyl, (C-C)alkynyl, or —(OCH2—CH2)—
interrupted between two carbons with one, two, or three (CCs)cycloalkyl, heterocycle, or (Co-Co)aryl groups; and W
(and/or A if one or both W groups is absent) is linked to the
corresponding location of Formula I.
The pyranyl group of Formula I can be any monosaccha
ride moiety. Typical monosaccharides include allose, altrose,
glucose, mannose, gulose, idose, galactose, or talose. Other

saturated, monounsaturated, or polyunsaturated, and can be
branched or unbranched. The fatty acid moiety can include
varying carbon chain lengths ranging from about Cs to C.
Common fatty acid moieties include Saturated fatty acids
Such as lauric acid (dodecanoic acid), myristic acid (tetrade
canoic acid), palmitic acid (hexadecanoic acid), steric acid
(octadecanoic acid), arachidic acid (eicosanoic acid), and
lignoceric acid (tetracosanoic acid); unsaturated acids such as
palmitoleic (a C16 acid), and oleic acid (a C18 acid); poly
unsaturated acids such as linoleic acid (a di-unsaturated C18
acid), linolenic acid (a tri-unsaturated C18 acid), and arachi
donic acid (a tetra-unsubstituted C20 acid). The carbon chain
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The R group of Formula I is an amino acid residue. The
term "amino acid refers to a natural amino acid residue (e.g.
Ala, Arg, ASn, Asp, Cys, Glu, Gln, Gly, His, Hyl, Hyp, Ile,
Leu, Lys, Met, Phe, Pro, Ser. Thr, Trp, Tyr, and Val) in D or L
form, as well as an unnatural amino acid (e.g. phosphoserine;
phosphothreonine; phosphotyrosine; hydroxyproline;
gamma-carboxyglutamate; hippuric acid; octahydroindole
2-carboxylic acid; statine; 1,2,3,4,-tetrahydroisoquinoline-3carboxylic acid; penicillamine; ornithine; citruline; C.-me
thyl-alanine; para-benzoylphenylalanine; phenylglycine;
propargylglycine; sarcosine; tert-butylglycine; and 2,5-di
aminohexanedioic acid) residue having one or more open
Valences. The term also comprises natural and unnatural
amino acids bearing nitrogen protecting groups (e.g. acetyl.
acyl, trifluoroacetyl, benzyloxycarbonyl, for Fmoc), as well
as natural and unnatural amino acids protected at carboxy
with oxygen protecting groups (e.g. as a (C-C)alkyl, phenyl
or benzyl ester or amide).
In some embodiments, X is oxygen and R is oxygen
linked serine, threonine, or tyrosine. In other embodiments, X
is sulfur and R is sulfur-linked cysteine. The amino group of
the serine, threonine, tyrosine, or cysteine can be protected
with a nitrogen protecting group, Such as an acyl, alkyl, or
carbamate group.
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The invention also provides compounds where the com
pound of Formula I is a compound of Formula II:
(II)

16
In another specific embodiment of the invention, the com
pound is:
24

5

O

O

O

OH

O
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HO

O

OH,

NHFmoc

O

OH

O
OMe

)12

15

wherein n is 0, 1, 2, or 3; and P is a nitrogen protecting group;
or a pharmaceutically acceptable salt or Solvate thereof. In
Some embodiments, P can bed an Fmoc group.
The invention further provides compounds where the com
pound of Formula II is a compound of Formula III:

or a salt or solvate thereof.

The invention also provides compositions that include a
compound described herein and a pharmaceutical carrier,
diluent, or excipient. The composition can be formulated, for
example, for intraperitoneal injection or infusion to a mam
mal.
25

(III)

O

Thus, the invention provides a new class Lipid A analogues
with structurally simplified carbohydrate-amino acid conju
gates. In some embodiments, the conjugates comprise a
monosaccharide code, hydrophobic side chains, and amino
acid ionic motif, having Formula IV:

O

O
HO

RO

O O

R2O

OH:

(IV)

O

N

O

H1NP

O

OH
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HO
RO

OMe

O

NHR

RO OMe
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where R' is a nitrogen-protecting group, such as acyl,
alkyl, or a carbamate (e.g., Fmoc); and R and R are each

or a pharmaceutically acceptable salt or Solvate thereof.

The groups RandR can be, for example, (Co-Cs)alkyl,

(Co-Cs)alkenyl, or (Co-Cs)alkanoyl groups, optionally
substituted on carbon with one or more substituents as
described above for the definition of substituent. In certain

45

specific embodiments, R and R are tetradecanoyl groups,
tetradecanyl groups, or a combination thereof.
In one specific embodiment of the invention, the compound

50

is:
19
55

NHFmoc
60

independently alkyl, acyl, alkenyl, aryl, heteroaryl, or
cycloalkyl groups. By “independently selected, the skilled
artisan will appreciate that each and every group may be
selected from the entire list set forth as possible selections
without regard to the selections of other groups having the
same or different appellations.
Preparation of Conjugates of the Invention.
General Synthetic Methods. Preparation of the compounds
described herein can be prepared according to the methods in
the Examples below, or may be prepared according to known
techniques in the art of organic synthesis. Many saccharides,
amino acids, and linking groups are commercially available,
and/or can be prepared as described in the art. Information
regarding general synthetic methods that may be used to
prepare the compounds described herein, particularly with
respect employing linking groups, may be found in Greg T.
Hermanson, Bioconjugate Techniques, Academic Press, San
Diego, Calif. (1996). Additional useful reactions well known
to those of skill in the art are referenced in March's Advanced

Organic Chemistry Reactions, Mechanisms, and Structure,
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or a salt or solvate thereof.

5' Ed. by Michael B. Smith and Jerry March, John Wiley &
Sons, Publishers; and Wuts et al. (1999), Protective Groups in
Organic Synthesis, 3" Ed., John Wiley & Sons, Publishers.
The methods of preparing compounds of the invention can
produce isomers in certain instances. Although the methods

US 9,120,838 B2
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of the invention do not always require separation of these
isomers, such separation may be accomplished, if desired, by
methods known in the art. For example, preparative high
performance liquid chromatography methods may be used
for isomer purification, for example, by using a column with
a chiral packing.
A variety of monosaccharide-amino acid conjugates were
prepared for evaluation. For one set of embodiments, the
synthesis began with the conversion of methyl C-D-glucopy
ranoside 6 into methyl 2,3-di-O-benzyl-O-D-glucopyrano
side 7 via sequential 4.6-benzylidene acetal formation, 2.3dibenzylation, and acetal cleavage accomplished in 67%
yield over three steps (Schemes 1 and 2). 4,6-Diiol 7 was then
regioselectively succinoylated at the primary position with
Succinic anhydride in the presence of 4-dimethylaminopyri
dine (DMAP) in pyridine to afford derivative 8 in 71% yield.
The carboxyl moiety of the linker was then coupled with
3-hydroxyl of protected L-serine derivative 9. This was
accomplished using N,N'-diisopropylcarbodiimide (DIC) as
the coupling reagent in the presence of DMAP in pyridine to
afford conjugate 10 in 80% yield.
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Scheme 1. Synthesis of monosaccharide-amino acid conjugate 10.
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Scheme 2. Synthesis of monosaccharide-amino acid conjugates 11-13.
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Having obtained a key construct, compound 10, further
functional group transformations were pursued. A driving
force for these synthetic manipulations was to obtain a series
of simple analogs that would allow for investigating the effect
of cationic and anionic character on LPS-antagonistic activity
in vitro. With this objective in mind, carboxylated compound
11 was obtained from 10 by cleavage of tert-butyl ester in
presence of TFA/DCM in 81% yield. Alternatively, the Fmoc
protecting group could also be removed from compound 10
with piperidine in DMF to afford free amine 12. Subse

20
quently, compound 13, having both carboxyl and amine
groups unprotected, was obtained. This was accomplished by
the treatment of compound 12 with TFA/CHCl to give
derivative 13 in 75% yield.
To gain further insight into the effect of various substitu
ents on endotoxic activity of monosaccharide-amino acid
conjugates, an analog of compound 11 was obtained in which
benzyl groups have been replaced with acyl (myristoyl, C14)
fatty acid chains. The synthesis of lipidated analog 19 was
accomplished as depicted in Scheme 3.

Scheme 3. Preparation of monosaccharide-fatty acid-amino acid conjugate 19.
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Methyl glycoside 6 was protected as 4,6-O-(p-methoxy
benzylidene) acetal 14 by treatment with anisaldehyde dim
ethylacetal in presence of camphorsulfonic acid in 89% yield.
The acylation of 14 with myristoyl chloride in the presence of
pyridine furnished compound 15 in 85% yield. The ben
Zylidene ring in 15 was reductively opened by treatment with
BH-THF catalyzed with Cu(OTf) to obtain unexpected
product 16 lacking the C-2 acyl chain in 67% yield. The loss
of the acyl chain was rather unexpected, but this glitch was
overcome by regioselective acylation with Succinic anhy
dride in pyridine at the primary C-6 position followed by C-2
acylation with myristoyl chloride. This two-step one-pot pro
cedure allowed us to obtain compound 17 in 79% yield.
L-serine derivative 9 was linked to the carboxyl group of 17
of via DIC-mediated coupling in the presence of DMAP. The
monosaccharide-fatty acid-amino acid conjugate 18 was
obtained in 83% yield. Acid treatment of the fully protected

5

10

15

22
compound 18 led to concomitant cleavage of the p-methoxy
benzyl (PMB) group at C-4 and tert-butyl ester. As a result,
compound 19 was isolated in 75% yield.
For comparative biological studies, we also accomplished
the synthesis of alkylated analog 24 was performed as
depicted in Scheme 4. Intermediate 14 was di-alkylated at
C-2 and C-3 with myristyl bromide in presence of NaH to
afford compound 20 in a 72% yield. The benzylidene ring in
20 was reductively opened by treatment with BH-THF cata
lyzed with Cu(OTf) to obtain product 22 in 87%. Acylation
of 22 with succinic anhydride led to compound 22 in 89%
yield. L-serine derivative 9 was then linked to the carboxyl
group of 22 via DIC-mediated coupling in the presence of
DMAP. The resulting monosaccharide-amino acid conjugate
23 was obtained in 79% yield. Acid treatment of the fully
protected compound 23 led to concomitant cleavage of the
p-methoxybenzyl (PMB) group at C-4 and tert-butyl ester. As
a result, target compound 24 was isolated in 81% yield.

Scheme 4. Synthesis of monosaccharide-alkyl-amino acid conjugate 24.
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Biological Activity. The inhibitory activity of the novel
conjugates on LPS-induced TNFC. production was investi
gated in vitro using THP-1 macrophages. THP-1 macroph
ages area useful system for studying inflammatory processes
and serve as a model for peripheral monocytes/macrophages
and their responses to bacterial infection. The cell viability
measurements (toxicity) of the novel conjugates were tested
using an XTT reduction assay. Table 1 in Example 2 below
Summarizes the biological data of the conjugates 11, 13, 19.
and 24 in comparison to the known Peri conjugate, 4. As
shown in Table 1, the potent inhibition displayed by the
inventive conjugate 24 of LPS-induced TNFC. production
without associated toxicity establishes the conjugates as use
ful therapeutic compounds in preventing the deleterious
effects of endotoxemia.
Pharmaceutical Formulations

The compounds described herein can be used to prepare
therapeutic pharmaceutical compositions. The compounds
may be added to the compositions in the form of a salt or
Solvate. For example, in cases where compounds are suffi
ciently basic or acidic to form stable nontoxic acid or base
salts, administration of the compounds as salts may be appro
priate. Examples of pharmaceutically acceptable salts are
organic acid addition salts formed with acids which form a
physiological acceptable anion, for example, tosylate, meth

15

25

30

35
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anesulfonate, acetate, citrate, malonate, tartrate. Succinate,

benzoate, ascorbate, C.-ketoglutarate, and O-glycerophos
phate. Suitable inorganic salts may also be formed, including
hydrochloride, halide, Sulfate, nitrate, bicarbonate, and car
bonate salts.

Pharmaceutically acceptable salts may be obtained using
standard procedures well known in the art, for example by
reacting a Sufficiently basic compound Such as an amine with
a Suitable acid to provide a physiologically acceptable ionic
compound. Alkali metal (for example, sodium, potassium or
lithium) or alkaline earth metal (for example, calcium) salts
of carboxylic acids can also be prepared by analogous meth

45

devices.
50

ods.

The compounds of the formulas described herein can be
formulated as pharmaceutical compositions and adminis
tered to a mammalian host, such as a human patient, in a
variety of forms. The forms can be specifically adapted to a
chosen route of administration, e.g., oral or parenteral admin
istration, by intravenous, intramuscular, topical or Subcuta
neOuS routes.

55

60

The compounds described herein may be systemically
administered in combination with a pharmaceutically accept
able vehicle, such as an inert diluent or an assimilable edible

carrier. For oral administration, compounds can be enclosed
in hard or soft shell gelatin capsules, compressed into tablets,
or incorporated directly into the food of a patient’s diet.
Compounds may also be combined with one or more excipi

ents and used in the form of ingestible tablets, buccal tablets,
troches, capsules, elixirs, Suspensions, syrups, wafers, and
the like. Such compositions and preparations typically con
tain at least 0.1% of active compound. The percentage of the
compositions and preparations can vary and may conve
niently be from about 2% to about 60% of the weight of a
given unit dosage form, often about 0.5 wt.% to about 20 wt.
% of a dosage form. The amount of active compound in Such
therapeutically useful compositions is such that an effective
dosage level can be obtained.
The tablets, troches, pills, capsules, and the like may also
contain one or more of the following: binders such as gum
tragacanth, acacia, corn starch or gelatin; excipients such as
dicalcium phosphate; a disintegrating agent Such as corn
starch, potato starch, alginic acid and the like; and a lubricant
Such as magnesium Stearate. A Sweetening agent such as
Sucrose, fructose, lactose or aspartame; or a flavoring agent
Such as peppermint, oil of wintergreen, or cherry flavoring,
may be added. When the unit dosage form is a capsule, it may
contain, in addition to materials of the above type, a liquid
carrier, such as a vegetable oil or a polyethylene glycol.
Various other materials may be present as coatings or to
otherwise modify the physical form of the solid unit dosage
form. For instance, tablets, pills, or capsules may be coated
with gelatin, wax, shellac or Sugar and the like. A syrup or
elixir may contain the active compound. Sucrose or fructose
as a Sweetening agent, methyl and propyl parabens as preser
Vatives, a dye and flavoring Such as cherry or orange flavor.
Any material used in preparing any unit dosage form should
be pharmaceutically acceptable and Substantially non-toxic
in the amounts employed. In addition, the active compound
may be incorporated into Sustained-release preparations and
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The active compound may be administered intravenously
or intraperitoneally by infusion or injection. Solutions of the
active compound or its salts can be prepared in water, option
ally mixed with a buffer or nontoxic surfactant. Dispersions
can be prepared in glycerol, liquid polyethylene glycols, tri
acetin, or mixtures thereof, or in a pharmaceutically accept
able oil. Under ordinary conditions of storage and use, prepa
rations may contain a preservative to prevent the growth of
microorganisms.
Pharmaceutical dosage forms suitable for injection or influ
sion can include sterile aqueous solutions, dispersions, or
sterile powders comprising the active ingredient adapted for
the extemporaneous preparation of sterile injectable or infus
ible solutions or dispersions, optionally encapsulated in lipo
somes. The ultimate dosage form should be sterile, fluid and
stable under the conditions of manufacture and storage. The
liquid carrier or vehicle can be a solvent or liquid dispersion
medium comprising, for example, water, ethanol, a polyol
(for example, glycerol, propylene glycol, liquid polyethylene
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glycols, and the like), vegetable oils, nontoxic glyceryl esters,
and suitable mixtures thereof. The proper fluidity can be
maintained, for example, by the formation of liposomes, by
the maintenance of the required particle size in the case of
dispersions, or by the use of surfactants. The prevention of the
action of microorganisms can be brought about by various
antibacterial and antifungal agents, for example, parabens,
chlorobutanol, phenol, Sorbic acid, thiomersal, and the like.
In many cases, it will be preferable to include isotonic agents,
for example, Sugars, buffers, or sodium chloride. Prolonged
absorption of the injectable compositions can be brought
about by agents delaying absorption, for example, aluminum
monostearate and/or gelatin.
Sterile injectable solutions can be prepared by incorporat
ing the active compound in the required amount in the appro
priate solvent with various of the other ingredients enumer
ated above, as desired, followed by filter sterilization. In the
case of sterile powders for the preparation of sterile injectable
Solutions, methods of preparation can include vacuum drying
and freeze drying techniques, which yield a powder of the
active ingredient plus any additional desired ingredient
present in the previously sterile-filtered solutions.
For topical administration, compounds may be applied in
pure form, e.g., when they are liquids. However, it will gen
erally be desirable to administer the active agent to the skinas
a composition or formulation, for example, in combination
with a dermatologically acceptable carrier, which may be a
Solid or a liquid.
Useful solid carriers include finely divided solids such as
talc, clay, microcrystalline cellulose, silica, alumina, and the
like. Useful liquid carriers include water, dimethyl sulfoxide
(DMSO), alcohols, glycols, or water-alcohol/glycol blends,
in which a compound can be dissolved or dispersed at effec
tive levels, optionally with the aid of non-toxic surfactants.
Adjuvants such as fragrances and additional antimicrobial
agents can be added to optimize the properties for a given use.
The resultant liquid compositions can be applied from absor
bent pads, used to impregnate bandages and other dressings,
or sprayed onto the affected area using a pump-type or aerosol
sprayer.

Thickeners such as synthetic polymers, fatty acids, fatty
acid salts and esters, fatty alcohols, modified celluloses, or
modified mineral materials can also be employed with liquid
carriers to form spreadable pastes, gels, ointments, Soaps, and
the like, for application directly to the skin of the user.
Examples of dermatological compositions for delivering
active agents to the skin are known to the art; for example, see
U.S. Pat. No. 4,992.478 (Geria), U.S. Pat. No. 4,820,508
(Wortzman), U.S. Pat. No. 4,608.392 (Jacquet et al.), and U.S.
Pat. No. 4.559,157 (Smith et al.). Such dermatological com
positions can be used in combinations with the compounds
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mg/m of active ingredient per unit dosage form. The desired
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scope. One skilled in the art will readily recognize that the
Examples Suggest many other ways in which the invention
could be practiced. It should be understood that numerous
variations and modifications may be made while remaining
within the scope of the invention.
EXAMPLES

45

Example 1
Chemical Synthesis of Compounds
General

50

55

Column chromatography was performed on silica gel 60
(70-230 mesh), reactions were monitored by TLC on Kiesel
gel 60 F2s. The compounds were detected by examination
under UV light and by charring with 10% sulfuric acid in
methanol. Solvents were removed under reduced pressure at
<40° C. CHC1 and CHCN were distilled from CaH,
directly prior to application. Pyridine was dried by refluxing
with CaH and then distilled and stored over molecular sieves

(3 A). Cu(OTf), was co-evaporated with toluene (3x10 mL)

60

and dried in vacuo for 2-3 h directly prior to application.
N,N'-Diisopropylcarbodiimide, 4-dimethylaminopyridine,
piperidine, and anhydrous DMF were used without further
conditioning. Optical rotations were measured using a Jasco
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tra were recorded in CDC1 at 300 MHz (Bruker Avance) or at

with the route of administration, the nature of the condition
or clinician.

dosage form, for example, containing 5 to 1000 mg/m, con
veniently 10 to 750 mg/m, most conveniently, 50 to 500

vaccine adjuvants.
The following Examples are intended to illustrate the
above invention and should not be construed as to narrow its

being treated, and the age and condition of the patient, and
will be ultimately at the discretion of an attendant physician
The compound can be conveniently administered in a unit

Pharmaceutical formulations that include a compound
described herein can also be provided as vaccine adjutants. A
vaccine adjuvant can be a therapeutic cancer vaccine adju
vant, such as for the treatment of breast, lung, colon, skin,
kidney, prostate, and other cancers. For example, a compound
described herein can act as an adjuvant that activates antigen
presenting cells to stimulate immune responses. Additional
information and techniques that may be applied to using the
compounds described herein as vaccine adjuvants are
described by, for example, Buskas et al. (Immunotherapy for
cancer. Synthetic carbohydrate-based vaccines, Chem. Com
mun. 2009, 5335-5349); and PCT Publication No. WO 2011/
156774 (Danishefsky et al.; Multivalent glycopeptide con
structs and uses thereof; and U.S. Provisional Application No.
61/353.722, filed Jun. 11, 2010). Accordingly, compounds
described herein that stimulate inflammation can be used as

described herein.

Useful dosages of the compounds described herein can be
determined by comparing their in vitro activity, and in vivo
activity in animal models. Methods for the extrapolation of
effective dosages in mice, and other animals, to humans are
known to the art; for example, see U.S. Pat. No. 4,938,949
(Borchet al.). The amount of a compound, oran active salt or
derivative thereof, required for use in treatment will vary not
only with the particular compound or salt selected but also

dose may conveniently be presented in a single dose or as
divided doses administered at appropriate intervals, for
example, as two, three, four or more Sub-doses per day. The
sub-dose itself may be further divided, e.g., into a number of
discrete loosely spaced administrations.
The invention provides therapeutic methods of treating
endotoxemia in a mammal, which involve administering to a
mammal having endotoxemia an effective amount of a com
pound or composition described herein. A mammal includes
a primate, human, rodent, canine, feline, bovine, Ovine,
equine, Swine, caprine, bovine and the like. The ability of a
compound of the invention to treat endotoxemia may be
determined by using assays well known to the art. For
example, the design of treatment protocols, toxicity evalua
tion, data analysis, quantification of cell kill, and the like are

P-1020 polarimeter. Unless noted otherwise, 'H-NMR spec
500 MHz (Bruker ARX-500), C-NMR spectra and two

dimensional experiments were recorded in CDC1 at 75 MHz
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(Bruker Avance) or at 125MHz (Bruker ARX-500). HRFAB

28
125.4, 127.3, 127.9, 128.1, 128.2, 128.3, 128.7, 128.8, 138.2,

MS determinations were made with the use of JEOL, MSta

138.9, 141.5, 1440, 144. 1, 156.0, 168.5, 171.8, 172.6 ppm.
HR FAB MS M+Na" calcd for CHNONa 862.3415.

tion (JMS-700) Mass Spectrometer; matrix m-nitrobenzyl
alcohol, with NaI as necessary.
Methyl 2,3-di-O-benzyl-6-O-(3-carboxypropanoyl)C-D-glycopyranoside (8)
4-Dimethylaminopyridine (DMAP 32 mg, 0.26 mmol)
and succinic anhydride (0.16 g, 1.56 mmol) were added to a
stirred solution of methyl 2,3-di-O-benzyl-O-D-glucopyra
noside 7 (Bazinet al., J. Org. Chem. 1999, 64, 144-152) (0.5
g, 1.3 mmol) in dry pyridine (5 mL) and the resulting mixture
was stirred for 16 hat rt (-23°C.) under argon. After that, the
reaction mixture was concentrated under the reduced pres
sure, the residue was dissolved in CHCl (30 mL) and
washed with water (3x15 mL). The organic phase was sepa
rated, dried over MgSO filtered and concentrated in vacuo.
The residue was purified by column chromatography on silica
gel (ethyl acetate-hexane gradient elution) to give the title
compound 8 (0.45 g, 0.95 mmol) as a colorless syrup in 71%

yield. Analytical data for 8: R, 0.43 (ethyl acetate); C. '-7.199 (c-10, CHC1); H NMR (300 MHz, CDC1): 8 2.60
(m, 4H, 2xCH), 3.38 (s.3H, OCH,), 3.44 (dd. 1H, J, 9.5
Hz, H-2), 3.51 (dd. 1H, Jas-9.5 Hz, H-4), 3.73 (m, 1H,
Js, 4.8 Hz, H-5), 3.80 (dd. 1H, J, 9.2 Hz, H-3), 4.26 (dd.
1H, J, 10.0 Hz, H-6a), 4.42 (dd. 1H, H-6b), 4.61 (d. 1H,

found 862.3432.

Methyl 2,3-di-O-benzyl-6-O-(4-((S)-2-(9-fluorenyl
methoxyearbonyl)amino-2-carboxyethyl)oxy-4-OX
obutanoyl)-C-D-glycopyranoside (11)
10

15

yield. Analytical data for 11: R-0.5 (methanol/ethyl acetate,
1/4, v/v); C+22.5° (c=1.0, CHCl); H NMR (500 MHz,

25

30

CDC1): 8,55.4, 63.7, 69.4, 69.9, 73.3, 75.3, 79.7,810, 98.3,
128.0, 128.1, 128.2, 128.5, 128.6, 128.7, 138.1, 138.6, 172.6,
497.1788. found 497.1770.
35

Methyl 2,3-di-O-benzyl-6-O-(4-((S)-2-(9-fluorenyl
methoxyearbonyl)amino-3-(tert-butoxy)-3-oxopro
pyl)oxy-4-oxobutanoyl)-O-D-glycopyranoside (10)
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syrup in 92% yield. Analytical data for 12: R, 0.62 (metha
nol/ethyl acetate, 1/9, v/v); C+17.3° (c=1.0, CHCl); H
NMR (500 MHz, CDC1): 8=1.49 (s.9H, t-Bu), 2.52-2.66 (m,
3H), 2.73-2.78 (m, 1H), 3.02 (broads, 1H, OH), 3.38 (s.3H,

OCH), 3.46 (d. 1H, J, 9.4 Hz, H-2), 3.50 (ddd, 1H,
50

/2CHPh), 4.77 (dd, 2H, J=11.5 Hz, CHPh), 4.99 (d. 1H,

55

6.95 Hz, Ser-NH),

7.27-7.31 (m. 10H, aromatic) ppm. C NMR (125 MHz,
CDC1): 8, 28.2, 29.8, 31.0, 31.1, 55.5, 55.7, 63.3, 63.6, 69.5,
69.8, 73.5, 75.9, 79.8, 81.5, 83.0, 98.5, 128.1, 128.2, 128.3,

128.4,128.7 (x2), 138.2, 138.7, 169.6, 1720, 173.1 ppm; HR
FABMSM+Na" calcd for CHNO, Na 640.2734. found
60

640.2741.

Methyl 2,3-di-O-benzyl-6-O-(4-((S)-2-amino-2-car
boxyethyl)oxy-4-oxobutanoyl)-O-D-glycopyranoside
(13)

4.61 (d. 1H, J, 3.2 Hz, H-1), 4.64 (d. 1H, J–12.1 Hz,

/2CHPh), 4.75 (dd, 2H, J=12.0 Hz, CHPh), 4.98 (d. 1H,

J’=11.3 Hz, /2CHPh), 4.75 (d. 1H, J, 8.0 Hz, Ser-NH),
69.4, 70.1, 73.4, 75.7, 79.7, 81.3, 83.3, 98.4, 120.2, 125.4,

Jas-9.5 Hz, H-4), 3.75 (m, 2H, H-5, Ser-CPH), 3.80 (m. 2H,
H-3, Ser-CPH), 4.18 (dd. 1H, J-10.19 Hz, H-6a), 4.46
(m. 1H, Ser-CH), 4.52 (dd. 1H, J, 4.19 Hz, H-6b), 4.61
(d. 1H, J, 3.53 Hz, H-1), 4.65 (d. 1H, J–12.5 Hz,
J°=9.0Hz, /2CHPh), 6.49 (d. 1H, J,

J-9.0, H-2), 3.73 (m. 1H, H-5), 3.78 (dd. 1H, J, 9.1 Hz,

7.27-7.77 (m. 18H, aromatic) ppm. ICNMR (125 MHz,
CDC1): 8, 28.1, 29.1, 29.1, 47.3, 54.1, 55.5, 63.9, 64.8, 67.4,

Methyl 2,3-di-O-benzyl-6-O-(4-((S)-2-amino-3-(tert
butoxy)-3-oxopropyl)oxy-4-oxobutanoyl)-O-D-gly
copyranoside (12)
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NMR (300 MHz, CDC1): 8, 1.48 (s, 9H, t-Bu), 2.53 (br. s.
OH), 2.66 (m, 4H, 2xCH), 3.37 (s.3H, OCH), 3.42 (d. 1H,

H-3), 4.25 (m, 2H, H-6b, SerCP-H), 4.38 (m, 2H, H-6",
SerCP-H), 4.44 (m. 2H, CHFmoc), 4.52 (m. 1H, SerC-H),

M+Na" calcd for CHNONa 806.2789. found

Piperidine (0.5 mL) was added dropwise to a solution of
monosaccharide 10 (0.1 g, 0.12 mmol) in DMF (2.0 mL) and
the resulting mixture was stirred for 20 min at rt. After that,
the reaction mixture was concentrated in vacuo and co-evapo
rated with toluene (x3). The residue was purified by flash
column chromatography (ethyl acetate/hexane, 1/1, V/v) to
give the title compound 12 (67 mg, 0.1 mmol) as a yellow

reaction was stirred for 5-9 hat rt until no further conversion

powder in 80% yield. Analytical data for 10: R, 0.34 (ethyl
acetate/hexane, 1/1, V/v); O.7+12.1 (c=1.0. CHCl); H

1274, 127.5, 127.8, 127.9 (x2), 128.0, 128.3, 128.5, 138.9,
139.6, 141.1, 144.2, 156.0, 172.1, 172.2 ppm; HR FAB MS
806.278O.

177.2 ppm; HR FAB MS M+Na" calcd for C.H.O.Na

of the starting material could be detected by TLC analysis.
The reaction mixture was diluted with CHCl (20 mL),
washed with water (2x15 mL) and brine (15 mL). The organic
phase was separated, dried over MgSO4, filtered and concen
trated in vacuo. The residue was purified by column chroma
tography on silica gel (ethyl acetate-hexane gradient elution)
to afford the title compound 10 (0.34g, 0.41 mmol) as a white

aromatic) ppm; "C NMR (75 MHz, CDC1/(CD) SO, 2/1,

65.9, 69.8, 70.2, 71.8, 74.5, 79.4, 81.5, 97.3, 120.5, 125.5,

4.79 (m, 2H, CHPh), 4.99 (d. 1H, J=11.3 Hz, /2CHPh),

DMAP (12.7 mg, 0.01 mmol) and N,N'-diisopropylcarbo
diimide (DIC, 0.16 mL, 1.04 mmol) were added to a stirred
solution of O-tert-butyl N-fluorenylmethoxycarbonyl-Lserine ester 9 (Shiozaki et al., Tetrahedron, 2006, 62. 205
225; Peri et al., Angew. Chem., Int. Ed. 2007, 46,3308-3312)
(0.19 g, 0.52 mmol) in CHCl (4 mL). After 1 h, carboxylic
acid derivative 8 (0.29 g, 0.62 mmol) was added and the

CDC1/(CD) SO, 2/1, v/v): 8–2.49-2.54 (m, 4H), 3.26 (s,
3H, OCH), 3.39 (m, 2H), 3.57 (m, 2H), 4.01 (br. s. 1H), 4.12
(m. 2H), 4.22 (m. 2H), 4.32 (dd, 2H, J=6.6 Hz), 4.43 (d. 1H,
J=5.1 Hz), 4.60 (s. 2H), 4.76 (m, 2H), 7.24-7.93 (m, 18H,
v/v): 8, 28.8, 28.9, 31.1, 47.0, 54.7, 54.8, 63.4, 63.9, 65.3,

J.-3.5 Hz, H-1), 4.65 (d. 1H, J–12.1 Hz, /2CH.Ph), 4.74

7.26-7.36 (m. 10H, aromatic) ppm; "C NMR (75 MHz,

Conjugate 10 (0.25 g, 0.29 mmol) was dissolved in TFA/
wet CHCl (1/5, V/V, 2 mL) and the resulting mixture was
stirred for 2 hat rt. After that, the volatiles were evaporated
under the reduced pressure, the residue was diluted with
CHCl (5 mL) and neutralized with triethylamine (until pH
~7). The volatiles were removed under the reduced pressure
and the residue was purified by column chromatography on
silica gel (ethyl acetate/hexane, 1/1, V/v) to afford the title
compound 11 (0.18 g., 0.24 mmol) as a white foam in 81%
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Conjugate 12 (0.1 g, 0.12 mmol) was dissolved in TFA/wet
CHCl(1/5, V/V, 2 mL) and stirred for 2 h. Upon completion
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29
as assessed by TLC analysis, solvents were evaporated in
vacuo. The residue was dissolved in CHCl (5 mL) and
neutralized with triethylamine (until pHs7). Solvents were
removed under the reduced the pressure. The residue was
Subjected to column chromatography on silica gel (methanol
ethyl acetate gradient elution) to obtain product 13 (50 mg.
0.09 mmol) as white foam in 75% yield. Analytical data for

30

78.5° (c=1.0, CHC1); H NMR (300 MHz, CDC1): 8=0.88
(t,3H, J–7.02 Hz, CH), 1.24 (br. s. 20H, 10xCH), 1.63 (m,
2H, CH), 1.97 (br. s. 1H, OH), 2.23-3.82 (m,3H, CH, OH),
3.41 (s.3H, OCH), 3.52-3.82 (m, 5H, H-2, 4, 5, 6a, 6b), 3.79
(s.3H, OCH), 4.57 (dd, 2H, J=12.4 Hz, CHPh), 4.75 (d. 1H,

J–3.7 Hz, H-1), 5.30 (dd. 1H, J–9.1 Hz, H-3), 6.85 (d. 2H,
'C NMR (75 MHz, CDC1): 8=14.3, 22.9, 25.1, 29.3, 29.5

J=8.6 Hz, aromatic), 7.20 (d. 2H, J=8.6 Hz, aromatic) ppm.

13: R-0.5 (methanol/ethyl acetate, 1/4, V/v); H NMR (500

MHz, DO): 8, 1.68 (m, 2H), 1.82 (m,3H), 2.73 (m, 4H), 3.19
(dd, 3H, J=5.7 Hz), 3.4 (s.3H, OCH), 3.58 (ddd, 2H, J=9.5,
100 Hz), 3.80 (dd. 1H, J=9.2 Hz), 3.87 (d. 3H, J=4.7 Hz),
4.33-4.37 (m,2H, J=4.7 Hz), 4.54 (d. 1H, J=10.9 Hz), 7.44 (s,

10

HR FAB MS M+Na" calcd for C.H.O.Na 547.3247.

found 547.3254.

10H, aromatic) ppm: 'C NMR (125 MHz, DO): 8, 21.9,

22.6, 29.5, 30.5, 44.9, 55.4, 62.4, 69.8, 73.4, 75.5, 79.1, 81.1,
97.8, 128.7, 128.8, 129.0, 129.1, 137.7, 137.9, 174.5, 175.1,

(x2), 29.6, 29.7, 29.8, 29.9, 32.1, 34.7, 55.4, 55.5, 61.7, 71.0,
71.9, 74.3, 74.9, 99.6, 114.0, 129.6, 130.1, 159.5, 174.3 ppm;

15

176.2 ppm; HR FAB MS M+Na" calcd for CHNO, Na

Methyl 6-O-(3-carboxypropanoyl)-4-O-p-methoxy
benzyl-2,3-di-O-tetradecanoyl-C-D-glucopyranoside
(17)

584.2108. found 584.2104.

DMAP (8.1 mg 0.06 mmol) and succinic anhydride (67
mg, 0.67 mmol) were added to a stirred solution of derivative
16 (0.35 g, 0.67 mmol) in dry pyridine (5 mL) and the result
ing mixture was stirred for 16 hat rt under argon. After that,
myristoyl chloride (0.21 ml, 0.80 mmol) was added dropwise,

Methyl 4,6-O-(p-methoxybenzylidene)-2,3-di-Otetradecanoyl-C-D-glucopyranoside (15)
Myristoyl chloride (2.34 mL, 8.67 mmol) and DMAP (70
mg, 0.57 mmol) were added to a stirred solution of methyl
4,6-O-(p-methoxybenzylidene)-O-D-glucopyranoside 14
(Christ et al., Science, 1995,268,80-83) (1.0g, 2.89 mmol) in
pyridine (15 mL) at 0°C. The mixture was stirred under an
atmosphere of argon for 16 h. Upon completion, the reaction

and the reaction mixture was stirred for 2 hatrt. After that, the
25

mixture was concentrated in vacuo. The residue was dis

solved in CHCl (30 mL), and washed with 1N HCl (2x15
mL), water (2x15 mL) and brine (15 mL). The organic phase
was separated, dried over MgSO filtered and concentrated
in vacuo. The residue was purified by column chromatogra
phy on silica gel (ethyl acetate-hexane gradient elution) to
afford derivative 15 (1.81 g, 2.48 mmol) as a white foam in

86% yield. Analytical data for 15: R, 0.47 (ethyl acetate/
hexane, 3/7, v/v); C+23.6° (c=1.0, CHCl); H NMR

30

data for 17: R, 0.55 (ethyl acetate-hexane 1/1, v/v); C.'+
42.4° (c=1.0, CHCl); H NMR (300 MHz, CDC1): 8, 0.87

35

(300 MHz, CDC1): 8, 0.88 (t, 6H, 2xCH), 1.26 (br. S. 40H,
20xCH), 1.59 (m, 4H, 2xCH), 2.29 (m, 4H, 2xCH), 3.40

(s.3H, OCH), 3.62 (dd. 1H, Jas-9.7 Hz, H-4), 3.75 (dd. 1H,
J-10.2 Hz, H-6a), 3.78 (s.3H, OCH), 3.92 (m. 1H, H-5),
4.28 (dd. 1H, Jse 4.7 Hz, H-6b), 4.82-2.94 (m. 2H, H-1, 2),
5.46 (s, 1H, >CHPh), 5.60 (dd. 1H, J, 9.7 Hz, H-3), 6.86 (d.
2H, J=8.8 Hz, aromatic), 7.25 (d. 2H, J=8.7 Hz, aromatic)
ppm; "C NMR (75 MHz, CDC1): 8, 14.3, 22.9, 25.1, 25.3,
29.2 (x2), 29.4, 29.5 (x2), 29.6, 29.7, 29.8, 29.9, 32.1, 34.3,

40

2xCH), 3.36 (s.3H, OCH), 3.59 (dd. 1H, Jas-9.5 Hz, H-4),
3.90 (m. 1H, H-5), 428(dd, 2H, Js, 4.4 Hz, J-11.5 Hz,
H-6a, 6b), 4.44 (d. 1H, J’=10.7 Hz, /2CHPh), 4.54 (d. 1H,
J°=10.7, /2CHPh), 4.87 (im, 2H, H-1, 2), 5.55 (dd. 1H,
J, 9.5 Hz, H-3), 6.84 (d. 2H, J–8.7 Hz, aromatic), 7.16 (d.
2H, J=8.6 Hz, aromatic) ppm: 'CNMR (75 MHz, CDC1): 8,
75.7. 96.9, 114.0, 129.5, 129.8, 159.6, 1717, 172.8, 173.7

45

ppm; HR FAB MS M+Na" calcd for C.H.O.Na
857.5391 found 857.541O.

97.8, 101.6, 113.7, 127.6, 129.6, 160.2, 172.6, 173.4 ppm;

HR FAB MS M+Na" calcd for CHONa 755.5074.
found 755.5090.
50

Methyl 4-O-p-methoxybenzyl-3-O-tetradecanoyl-C.D-glucopyranoside (16)

data for 16: R, 0.40 (ethyl acetate/hexane, 7/3, V/v);C) '--

(t, 6H, 2xCH), 1.25 (br. S. 40H, 20xCH), 1.59 (m, 4H,
2xCH), 2.26 (m. 2H, CH), 2.33 (m. 2H, CH), 2.61 (m, 4H.

14.3, 22.8, 25.1, 28.8, 29.2, 29.3, 29.4 (x2), 29.5, 29.6, 29.7,
29.8, 32.1, 34.2, 34.5 (x3), 55.4, 62.7, 68.6, 71.8, 71.9, 74.3,

34.5, 55.4, 55.5, 62.5, 68.8, 68.9, 71.6, 76.8, 77.2, 77.6, 79.5,

A 1 M solution of BH-THF in tetrahydrofuran (5 mL, 5
mmol) was mixed with compound 15 (0.75 g, 1.02 mmol) and
the resulting mixture was stirred for 10 min at rt under argon.
Freshly conditioned copper(II) trifluoromethanesulfonate
(18 mg, 0.05 mmol) was added, and the reaction mixture was
stirred for 2 hatrt. After that, the reaction mixture was cooled
to 0°C. and then quenched by sequential addition of triethy
lamine (0.14 mL, 1 mmol) and methanol (1.8 mL). The result
ing mixture was concentrated under the reduced pressure
followed by co-evaporation with methanol. The residue was
purified by flash column chromatography on silica gel (ethyl
acetate-hexane gradient elution) to give the title compound 16
(0.35 g, 0.67 mmol) as white solid in 67% yield. Analytical

resulting mixture was concentrated under the reduced pres
sure. The residue was dissolved in CHCl (30 mL) and
washed successively with 1N HCl (2x15 mL), water (2x15
mL) and brine (15 mL). The organic phase was separated,
dried over MgSO filtered and concentrated in vacuo. The
residue was purified by column chromatography on silica gel
(ethyl acetate-hexane gradient elution) to give compound 17
(0.43g, 0.52 mmol) as white syrup in 79% yield. Analytical

55
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Methyl 6-O-(4-((S)-2-(9-fluorenylmethoxyearbonyl)
amino-3-(tert-butoxy)-3-oxopropyl)oxy-4-oxobu
tanoyl)-2,3-di-O-tetradecanoyl-C-D-glucopyranoside
(18)
DMAP (9.5 mg 0.07 mmol) and DIC (0.12 mL, 0.78
mmol) were added to a stirred solution of O-tert-butyl-Nfluorenylmethoxycarbonyl-L-serine 9 (Shiozaki et al., Tetra
hedron, 2006, 62,205-225; Penet al., Angew. Chem., Int. Ed.,
2007, 46,3308-3312) (0.15g, 0.39 mmol) in CHCl (3 mL).
After 1 h, the carboxylic acid derivative 17 (0.39 g, 0.46
mmol) was added and the reaction was stirred for 5-9 hat rt no
further conversion of the starting material could be detected
by TLC analysis. The reaction mixture was diluted with
CHCl (20 mL), washed with water (2x10 mL) and brine (10
mL). The organic phase was separated, dried over MgSO,
filtered and concentrated in vacuo. The residue was purified
by column chromatography on silica gel (ethyl acetate-hex
ane gradient elution) to afford the title compound 18 (0.38g.
0.32 mmol) as a white solid in 83% yield. Analytical data for
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18: R, 0.5 (ethyl acetate/hexane, 3/7, V/v); C+25.7°
(c=1.0, CHCl); H NMR (300 MHz, CDC1): 8, 0.88 (t, 6H,

3.30 (dd. 1H, J, 9.7 Hz, H-2), 3.38 (s.3H, OCH), 3.39 (m,

H-4), 3.59-3.76 (m, 5H, H-3, 5, OCH, OCH), 3.80 (s.3H,

OCH), 3.86 (m, 1H, OCH'), 4.28 (m, 2H, Js 4.7 Hz,
Js 2.3 Hz, J-12.0 Hz, H-6a, 6b), 4.49 (d. 1H, J’=10.5

2xCH), 1.25 (br. S. 40H, 20xCH), 1.49 (s.9H, t-Bu), 1.59
(m, 4H, 2xCH), 1.59 (m, 4H, 2xCH), 2.30 (m, 4H, 2xCH),

3.37 (s.3H, OCH,), 3.48 (dd. 1H, J, 9.5 Hz, H-4), 3.76 (s,
Ser-CPH), 4.35-4.55 (m, 6H, CHPh, Ser-CH, Ser-CPH,
CHFmoc), 4.90 (m, 2H, H-1, 2), 5.58 (dd. 1H, J, 9.7 Hz,

Hz, 4CH.Ph), 4.76 (d. 1H, J, 3.5 Hz, H-1), 4.81 (d. 1H,
J’=10.5 Hz, /2CHPh), 6.89 (d. 2H, J=8.9 Hz, aromatic), 7.22
(d. 2H, J=9.7 Hz, aromatic) ppm: 'C NMR (125 MHz,

3H, OCH), 3.90 (m. 1H, H-5), 4.16-4.26 (m, 3H, H-6a, 6b,
H-3), 5.82 (d. 1H, J,
8.3 Hz, Ser-NH), 6.18-7.77 (m,
12H, aromatic) ppm, ICNMR (75 MHz, CDC1): 8, 14.3,
22.8, 25.0, 28.0, 28.8, 29.0, 29.3 (x2), 29.4, 29.5, 29.6, 29.8,

10

176.5 ppm; HR FAB MS M+Na" calcd for C.H.O.Na
15

1222.7018. found 1222.7023.

Methyl 6-O-(4-((S)-2-(9-fluorenylmethoxyearbonyl)
amino-2-carboxyethyl)oxy-4-oxobutanoyl)-2,3-di-Otetradecanoyl-C-D-glucopyranoside (19)
Compound 18 (0.2g, 0.16 mmol) was dissolved in TFA/
wet CHCl (1/5, V/V, 4 mL) and stirred for 2 hat rt. After that,
the volatiles were evaporated in vacuo, the residue was
diluted with CHCl (5 mL) and neutralized with triethy
lamine (until pH -7). The volatiles were removed under the
reduced the pressure and the residue was purified by column
chromatography on silica gel (ethyl acetate/hexane, 1/1, V/v)
to afford the title compound 19 (0.13 g, 0.12 mmol) as a white

foam in 75% yield. Analytical data for 19: R, 0.5 (methanol
ethyl acetate 1/9, V/v); H NMR (300 Hz, CDC1): 8, 0.88 (t,
6H, 2xCH), 1.25 (br. S. 40H, 20xCH), 1.58 (m, 4H,
2xCH), 2.33 (m, 4H, 2xCH), 3.27 (br. s, 4H, 2xCH), 3.27
(br. s. 1H, OH), 3.38 (s.3H, OCH), 3.47 (dd. 1H, J, 9.4 Hz,
H-4), 3.83 (m. 1H, H-5), 4.21-4.51 (m, 7H, H-6a, 6b, Ser

25
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1H, H-4), 3.42-3.66 (m, 5H, H-3, 5, OCH, OCH), 3.67 (s,

40

45

26.4, 28.0, 28.9, 29.5, 29.6, 29.7, 29.8, 30.2, 30.7, 32.0, 47.0,
54.0, 55.2, 55.3, 64.7, 67.3, 68.6, 71.8, 73.8, 74.6, 80.8, 81.8,
83.0, 97.9, 99.7, 113.9, 120.1, 125.2, 125.3, 127.2, 1278,
129.9, 130.3, 1414, 142.5, 143.9, 155.9, 159.4, 168.4, 171.7,

175.1 ppm; HR FAB MS M+Na" calcd for CHs NO-Na
Methyl 6-O-(3-carboxypropanoyl)-4-O-p-methoxy
benzyl-2,3-di-O-tetradecanyl-C-D-glucopyranoside
(22)

NMR (300 MHz, CDC1): 8, 0.88 (t, 6H, 2xCH), 1.26 (br. s.
40H, 22xCH), 1.63 (m, 4H, 2xCH), 2.64 (m. 2H, 2xCH),

CDC1): 8, 0.88 (t, 6H, 2xCH), 1.17 (m, 40H, 20xCH), 1.38
(s, 9H, t-Bu), 1.54 (m, 4H, 2xCH), 2.53 (m, 4H, 2xCH),

3H, OCH), 3.79 (m. 1H, OCH), 4.11-4.46 (m, 8H, H-6a,
6b, /2CHPh, Ser-CH, Ser-CPH, CHFmoc), 4.66 (d. 1H,
J.-3.3 Hz, H-1), 4.71 (d. 1H, JP-10.5 Hz, /2CH.Ph), 5.71
(d. 1H, J, 8.1 Hz, Ser-NH), 6.75-7.64 (m. 12H, aro
matic) ppm: 'CNMR (75 MHz, CDC1): 8, 14.2, 22.8, 26.1,

1046.5817. found 1045.5822.

syrup in 89% yield. Analytical data for 22: R-0.55 (ethyl
acetate/hexane, 7/3, v/v): CI+42.9° (c=1.0, CHCl); H

DMAP (6.2 mg 0.05 mmol) and DIC (0.16 mL, 1.01
mmol) were added to a stirred solution of O-tert-butyl-Nfluorenylmethoxycarbonyl-L-serine 9 (0.39 g, 0.60 mmol) in
CHCl (3 ml). After 1 h, the carboxylic acid derivative 22
(0.41 g, 0.50 mmol) was added and the reaction was stirred for
5-9 huntil no further conversion of the starting material could
be detected by TLC analysis. The reaction mixture was
diluted with CHCl (20 mL), washed with water (2x10 mL)
and brine (10 mL). The organic phase was separated, dried
over MgSO filtered and concentrated in vacuo. The residue
was purified by column chromatography on silica gel (ethyl
acetate-hexane gradient elution) to afford the title compound
23 (0.47g, 0.40 mmol) as a colorless amorphous solid in 79%

3.18 (dd. 1H, J, 9.7 Hz, H-2), 3.26 (s.3H, OCH), 3.28 (m,

MHz, CDC1): 8, 25.0, 25.1, 28.9, 29.3 (x2), 29.4, 29.5, 29.6,

DMAP (7.0 mg 0.05 mmol) and succinic anhydride (71
mg, 0.70 mmol) were added to a stirred solution of methyl
4-O-p-methoxybenzyl-2,3-di-O-tetradecanyl-C-D-glucopy
ranoside 21 (Price et al., Proc. Natl. Acad. Sci., USA, 1995,
92, 7352-7356) (0.40 g, 0.56 mmol) in dry pyridine (5 mL)
and the resulting reaction mixture was stirred for 16 hat rt
under argon. After that, the reaction mixture was concentrated
under the reduced pressure. The residue was dissolved in
CHCl (30 mL) and washed successively with 1 NHCl (2x15
mL), water (2x15 mL) and brine (15 mL). The organic phase
was separated, dried over MgSO, filtered and concentrated
in vacuo. The residue was purified by column chromatogra
phy on silica gel (ethyl acetate-hexane gradient elution) to
give the title compound 22 (0.41 g, 0.50 mmol) as a colorless

Methyl 6-O-(4-((S)-2-(9-fluorenylmethoxycarbonyl)
amino-3-(tert-butoxy)-3-oxopropyl)oxy-4-oxobu
tanoyl)-2,3-di-O-tetradecanyl-O-D-glucopyranoside
(23)

yield. Analytical data for 23: R, 0.43 (ethyl acetate/hexane,
3/7, v/v); c)-36.1° (c=1.0, CHCl); H NMR (300 MHz,

CPH, Ser-CH, CH, Fmoc), 4.86 (m. 1H, H-2), 4.90 (br. s.
1H, H-1), 5.31 (dd. 1H, J, 9.1 Hz, H-3), 5.96 (br. s. 1H,
Ser-NH), 7.27-7.76 (m, 8H, aromatic) ppm: 'C NMR (75

29.8, 29.9, 32.1, 34.2, 34.5, 47.2, 55.5, 62.9, 64.3, 67.6, 69.4,
69.6, 69.9, 71.2, 72.7, 77.4, 96.8, 114.1, 120.2, 124.9, 125.3,
127.3, 127.9, 1414, 143.8, 143.9, 1717, 1718, 174.3, 174.6,

74.8, 80.9, 81.9, 98.1, 114.1, 130.1, 130.4, 159.6, 172.0,
829.5805. found 829.5806.

32.0, 34.2, 34.4, 47.2, 54.0, 55.3, 62.6, 67.4, 68.5, 71.7, 71.8,
74.3, 83.0, 96.8, 113.9, 120.1, 125.4, 127.2, 127.8, 129.3,
129.6, 1414, 144.0, 155.9, 159.5, 168.4, 171.5, 172.7, 173.5

ppm; HR FAB MS M+Na" calcd for CHNONa

CDC1): 8=14.3, 22.9, 26.2, 26.5, 28.8, 28.9, 29.5, 29.7, 29.8,
29.9 (x2), 30.3, 30.8, 32.1, 55.3, 55.5, 63.6, 68.8, 72.0, 74.1,

50
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1720, 181.3 ppm; HR FAB MS M+Na" calcd for
CHNO-Na 1194,7433. found 1194,7433.
Methyl 6-O-(4-((S)-2-(9-fluorenylmethoxycarbonyl)
amino-2-carboxyethyl)oxy-4-oxobutanoyl)-2,3-di-Otetradecanyl-C-D-glucopyranoside (24)
Conjugate 23 (0.2g, 0.17 mmol) was dissolved in TFA/wet
CHCl(1/5, V/V, 4 mL) and the resulting mixture was stirred
for 2 hat rt. After that, the volatiles were evaporated under the
reduced pressure, the residue was diluted with CHCl (5 mL)
and neutralized with triethylamine (until pH -7). The vola
tiles were removed under the reduced pressure and the residue
was purified by column chromatography on silica gel (ethyl
acetate/hexane 1/1, V/v) to obtain the title compound 24 (0.13
g, 0.14 mmol) as a white amorphous solid in 81% yield.

Analytical data for 24: R, 0.58 (methanol/ethyl acetate, 1.5/
8.5, v/v); C-34.9° (c=1.0, CHCl); H NMR (500 MHz,

65

CDC1/(CD) SO, 2/1, v/v): 8, 0.78 (t, 6H, 2xCH), 1.45 (br.
s, 40H, 20xCH), 1.47 (m, 4H, 2xCH), 2.5 (m, 4H, 2xCH),

3.10 (dd. 1H, J, 9.4 Hz, H-2), 3.22-3.33 (m, 7H), 3.41-3.51
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(m,3H), 3.55 (m. 1H, H-5), 3.64 (t, 2H, J=6.7 Hz), 4.14-4.32

34
respectively for 2 hat 37°C. in 5% CO. The cellular toxicity
was then assessed in a platereader using absorbance of

(m, 7H), 4.42 (d. 1H, J=9.5 Hz), 4.63 (d. 1H, J, 3.2 Hz,
ppm: 'C NMR (125 MHz, CDC1/(CD) SO, 2/1, v/v): 8,

reduced XTT at 467 nm.

H-1), 6.52 (br. s. 1H, Ser-NH), 7.22-7.82 (m, 8H, aromatic)
13.6, 21.9, 25.4, 25.5, 28.6, 28.8, 28.9, 29.0, 29.5 (x2), 31.2,
39.0, 39.2, 39.3, 39.5, 39.7, 39.8 (x2), 39.9, 40.0, 40.1, 46.6,
54.3, 63.4, 65.6, 69.2, 69.4, 70.6, 72.7, 79.6, 80.7, 97.3, 119.4,
124.6, 124.8, 126.6, 127.1, 140.1, 143.4, 155.4, 171.3, 171.6,

178.3, 178.7 ppm; HR FAB MS M+Na" calcd for
C.H.NO Na 1018.6232. found 1018.6182.
Example 2
Compound Analysis
Preparation of Compounds for Cellular Treatment.
Synthetic compounds in solid form were dissolved in tet
rahydrofuran (THF), aliquotted in small volumes, vacuum
centrifuged for 1 h and stored at -80° C. as dry compounds.
For cellular treatment, an aliquot was dissolved in an appro
priate volume of dimethylsulfoxide (DMSO) to give a con
centrated working Stock solution. This stock Solution was
further diluted in DMSO to give the desired concentration
range. The final concentration of DMSO in the cell treatments
was always maintained at 0.6%. Concentrations of Fmoc
containing compounds were verified by absorbance using an

10

15

25

extinction coefficient of 7800 MT cm at 301 nm.

Cell Culture and LPS Antagonism Assays.
THP-1 cells were obtained from ATCC (Manassas, Va.)
and maintained in RPMI-1640 culture medium (HyClone,
Logan, Utah) containing 2 mML-glutamine, 25 mM HEPES,
1.5 g/L sodium bicarbonate, 10% fetal bovine serum (FBS)
(HyClone), 50 units/mL penicillin, 50 lug/mL streptomycin
(HyClone), and 50 uM 3-mercaptoethanol at 37° C. in 5%
CO. For cellular assay, THP-1 monocytes were centrifuged
and resuspended in a fresh growth medium to a cell density of
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5x10 cells/mL Cells were then seeded in a 48-well plate and
differentiated into adherent macrophages by treatment with
10 ng/mL phorbol 12-myristate 13-acetate (PMA) (Sigma)
for 24 h at 37° C. in 5% CO. The non-adherent cells were
removed and the adherent cells were washed and replenished
with reduced FBS growth medium. For the two wells set aside
for calculating percent differentiation, the cells were washed
with PBS (Hyclone) prior to removal by 0.25% trypsin
EDTA. Cells in a separate well were removed with 0.25%
trypsin and counted under the microscope using a hemocy
tometer to determine the number of adherent macrophages.
For the remaining wells, the cells were pre-incubated with
LPS antagonist compounds at different concentrations for 30
min followed by addition of 10 ng/mL ultrapure LPS from E.
coli K12 (InvivoGen, San Diego, Calif.) for 6 h at 37°C. in
5% CO, 0.6% DMSO was used as a control. The cell medium
was collected and stored at -20°C. until analyzed by ELISA
for secreted TNFC. production.
Cell Viability Measurements.
Cell viability was monitored using an XTT 2,3-bis(2methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxa
nilide assay. Macrophage metabolic activity was assessed by
probing mitochondrial reduction of XTT (Sigma) which is a
measure of viability (or toxicity) in response to the synthetic
antagonists. Following 6 h treatment with antagonist com
pounds and LPS, the macrophages were washed with PBS
(Hyclone) and incubated with XTT (0.33 mg/mL) and phena
zine methosulfate (PMS) (8.3 uM) (Acros, Morris Plains,
N.J.) to a final concentration of 0.33 mg/mL and 8.3 uM
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Compound Evaluation.
The inhibitory activity of compounds 10-13 on LPS-in
duced TNFC. production was investigated in vitro using
THP-1 macrophages prepared as described above. THP-1
cells are an excellent system for studying inflammatory pro
cesses and serve as a model for peripheral monocytes/mac
rophages and their responses to bacterial infection. Com
pounds 10, 12, and 13 exhibited no inhibitory activity against
LPS-induced TNFC. production in the concentration range of
0.1 nM to 10 uM (FIG. 2A-C). These compounds were also
tested in the absence of LPS and demonstrated no agonist
activity. Compound 11, which has a free carboxylic group,
was able to significantly inhibit LPS-induced TNFC. produc
tion at concentrations greater than 10 uM (FIG. 3). Unfortu
nately, cell viability measurements using an XTT reduction
assay indicated that compound 11 was toxic to the cells in the
30-100 uM range. Although there was a notable gap between
inhibition and toxicity at 30 and 50 uM, the similarities
between the inhibition and toxicity curves suggested that
much of the antagonistic activity by 11 was related to toxicity.
Comparative studies were then performed using com
pounds 19 and 24, lipidated and alkylated analogs of com
pound 11, respectively. In addition, as a comparison point, the
standard positive control compound 4 (Peri et al.) was
obtained. Lipidated compound 19 displayed a marked
improvement in LPS-antagonistic ability Inhibition of LPS
induced TNFC. was found beginning at 550 nM 19 (FIG. 4). A
reproducible biphasic response was consistently seen in the
activity of 19. This may indicate multiple binding sites on the
macrophages, both higher and lower affinity for the antago
nist compound. 80% of the LPS response was blocked at 5uM
compound 19 with no observable toxicity. Cell viability
began to be compromised at 10M and some agonist activity
was found in the 10-30 uM range (FIG. 4).
The alkylated compound 24 was found to be a very effec
tive inhibitor of LPS-induced TNFC. production in human
macrophages (FIG. 5). 70% inhibition was observed at 1 uM
24 and overall inhibition reached 90% at 40 uM. Compound
24 exhibited no toxicity or agonist activity in the tested 0.2 to
40 LM range. Curve fitting of the inhibition data in FIG. 5
produced an ICso value of 470 nM. These results were supe
rior to those obtained with compound 4, which had an inhi
bition range from 3-10M and began to show agonist activity
at concentrations >10 uM (FIG. 6). Compound 4 was toxic at
high concentrations.
The potent inhibition displayed by compound 24 of LPS
induced TNFC. production without associated toxicity estab
lishes this compound and those in its class as significant
therapeutic and research compounds. These results extend the
work of Boons and co-workers with phosphateless Lipid A
derivatives by transitioning from disaccharide-based to
monosaccharide-based compounds. The ICso inhibition con
stant of 470 nM for compound 24 is the lowest reported for a
monosaccharide compound and its potency in human mac
rophages significantly improves on the monosaccharide com
pounds tested in mouse bone-marrow-derived macrophages
by Pen et al. While other compounds may have higher
potency, the value of the compounds described herein is
enhanced by their facile syntheses, which can be readily
modified for preparing other derivatives. Additionally, the
observation that replacement of the acyl chains in 19 with
alkyl chains (24) produced a significantly more potent
antagonist with less toxicity indicates that additional modifi
cations can further enhance the activity of the specific com
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pounds described herein. Furthermore, subtle structural
changes can have an impact on whether a particular com
pound displays antagonist or agonist activity. Adjuvants
using the compounds described herein may be prepared as
described by Deng et al. (J. Am. Chem. Soc., 2008, 130,
5860-5861), Maiti et al. (Eur: J. Org. Chem., 2010, 80-91),
and Tang et al. (Chem. Eur: J., 2010, 16, 1319-1325).
Studies described herein provide new Lipid A analogs, and
methods for inhibiting and preventing the deleterious effects
of endotoxemia. Results of the studies described herein, such
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(ii) Tablet 2
Sodium starch glycolate
Magnesium stearate
SOO.O
10

as those illustrated in Table 1, will have a far reaching impact
on the treatment of patients diagnosed with endotoxemia.
TABLE 1.

(iii) Capsule
15

Compound biological activity in human macrophage cells.
(IC.so)

Toxicity

Agonist activity

10, 12, 13
11

None observed
46M

None observed
>10 M

None observed
None observed

19

3 M

24

0.5 M

4

6M

>10 M

10-30 M

None observed

None observed

>30 M

30-100 M

30

(v) Injection 2 (10 mg/mL)

40

Pharmaceutical Dosage Forms
45

50

Compound X

1.ON Sodium hydroxide solution
(pH adjustment to 7.0–7.5)
Water for injection

Microcrystalline cellulose
Magnesium Stearate

92.5
3.0

55

Compound X (free acid form)
Monobasic sodium phosphate
Dibasic sodium phosphate
Polyethylene glycol 400
0.1N. Sodium hydroxide solution
(pH adjustment to 7.0–7.5)
Water for injection

(vi) Aerosol
Compound X
Oleic acid
Trichloromonofluoromethane
Dichlorodifluoromethane
Dichlorotetrafluoroethane

(vii) Topical Gel 1
Compound X
Carbomer 934
Triethanolamine

(pH adjustment to 5-7)
Methyl paraben

3OO.O

Purified water
60

Starch

q.S. ad 1 mL

mg/mL

C.S.

q.S. ad 1 mL

mg/can
2O
10

5,000
10,000
5,000

1OOO
77.5
1S.O
12.0

Compound X
Microcrystalline cellulose

1.O
12.0
0.7
4.5
C.S.

mg tablet

Lactose
Povidone
CroScarmellose sodium

(ii) Tablet 2

mg/mL

35

Example 3

(i) Tablet 1

Compound X (free acid form)
Dibasic sodium phosphate
Monobasic sodium phosphate
Sodium chloride

cells.

The following formulations illustrate representative phar
maceutical dosage forms that may be used for the therapeutic
or prophylactic administration of a compound, a composition
of the compound as described herein, or a pharmaceutically
acceptable salt or solvate thereof (hereinafter referred to as
Compound X):

Compound X
Colloidal silicon dioxide
Lactose

(iv) Injection 1 (1 mg/mL)
25

Accordingly, the compounds described herein can be used
as antagonists of LPS activity, Such as for treating patients
diagnosed with endotoxemia. For example, compound 24 is a
potent and non-toxicantagonist of lipopolysaccharide (LPS)induced inflammation in human macrophage cells, including
inflammation associated with endotoxemia, septic shock, or
Alzheimer's disease. The working concentration of the com
pounds can be in the low micromolar to Sub-micromolar
range and the compounds can be effective at blocking cytok
ine production by LPS (10 ng/mL) in human macrophage

mg capsule

Pregelatinized starch
Magnesium stearate

TNFC inhibition

Compound

mg tablet

59%
1.25%
C.S.
O.2%

q.S. to 100 g

mg tablet
2O.O
41O.O
SO.O
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(viii) Topical Gel 2
Compound X
Methylcellulose

59%
2%
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What is claimed is:

-continued

1. A compound of Formula I:
(viii) Topical Gel 2
Methyl paraben
Propyl paraben
Purified water

wt.%
O.2%
O.02%
q.S. to 100 g

(I)

OR3
R2O

OR
O

(ix) Topical Ointment
Compound X
Propylene glycol
Anhydrous ointment base
Polysorbate 80
Methyl paraben
Purified water

wt.%
59
196
40%
296
O.2%
q.S. to 100 g

O

10

RO

R

O

pi

x1

O

15

wherein

R" is (C-C)alkyl:
R and Rare each independently (Cs-C)alkyl; (Cs
C24)alkenyl; or (Cs-C24)alkanoyl;

R" is H., (C-C)alkyl, or aryl;
(x) Topical Cream 1
Compound X

wt.%

White beeswax

10%

Liquid paraffin
Benzyl alcohol
Purified water

30%
59
q.S. to 100 g

(xi) Topical Cream 2

n is 0-9:
X is O, S, or N:

59

R is an oxygen-linked, Sulfur-linked, or nitrogen-linked
amino acid that is optionally protected on oxygen or
nitrogen with an oxygen or nitrogen protecting group;
wherein any alkyl, alkenyl, alkanoyl oraryl is optionally
Substituted with one or more hydroxy, Oxo, alkyl,
alkoxy, alkylcarbonyl, alkylcarbonyloxy, nitro, halo,
trifluoromethyl, trifluoromethoxy, cyano, or amino

25

wt.%

groups:

30

Compound X
Stearic acid

59
10%

Glyceryl monostearate
Polyoxyethylene stearyl ether

3%
3%

Sorbitol

59

Isopropyl palmitate
Methyl Paraben
Purified water

296
O.2%
q.S. to 100 g

These formulations may be prepared by conventional pro
cedures well known in the pharmaceutical art. It will be
appreciated that the above pharmaceutical compositions may
be varied according to well-known pharmaceutical tech
niques to accommodate differing amounts and types of active
ingredient Compound X. Aerosol formulation (vi) may be
used in conjunction with a standard, metered dose aerosol
dispenser. Additionally, the specific ingredients and propor
tions are for illustrative purposes. Ingredients may be
exchanged for Suitable equivalents and proportions may be
varied, according to the desired properties of the dosage form
of interest.

While specific embodiments have been described above
with reference to the disclosed embodiments and examples,
such embodiments are only illustrative and do not limit the
Scope of the invention. Changes and modifications can be
made in accordance with ordinary skill in the art without
departing from the invention in its broader aspects as defined
in the following claims.
All publications, patents, and patent documents are incor
porated by reference herein, as though individually incorpo
rated by reference. No limitations inconsistent with this dis
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(II)
OR3
R2O

invention.

OH
O

50

O

O
RO

O

pi

O

O
55

OH

N

H1NP

wherein

R" is (C-C)alkyl;
R and R are each independently (Cs-Cal)alkyl; (Cs
60

C24)alkenyl; or (Cs-C24)alkanoyl;

n is 0, 1, 2, or 3; and

closure are to be understood therefrom. The invention has

been described with reference to various specific and pre
ferred embodiments and techniques. However, it should be
understood that many variations and modifications may be
made while remaining within the spirit and scope of the

or a pharmaceutically acceptable salt or Solvate thereof.
2. The compound of claim 1 wherein X is oxygen and R is
oxygen-linked serine, threonine, or tyrosine.
3. The compound of claim 1 wherein X is sulfur and R is
sulfur-linked cysteine.
4. The compound of claim 2 wherein the amino group of
the serine, threonine, or tyrosine is protected with a nitrogen
protecting group.
5. The compound of claim 4 wherein the nitrogen protect
ing group is an acyl, alkyl, or carbamate group.
6. The compound of claim 1 wherein the compound of
Formula I is a compound of Formula II:

65

P is a nitrogen protecting group;
or a pharmaceutically acceptable salt or Solvate thereof.
7. The compound of claim 6 wherein P is an Fmoc group.
8. The compound of claim 6 wherein the compound of
Formula II is a compound of Formula III:
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O

O

O

O

O
HO

O

R2O

5

OH:

O O

24

(III)
O

O

O

N

HO

H1NP

O 5

OH:

NHFmoc

O

OMe

O

10

OMe

)12

wherein

R and Rare each independently (Cs-Cal)alkyl; (Cs
C24)alkenyl; or (Cs-C24)alkanoyl;
and P is a nitrogen protecting group;
or a pharmaceutically acceptable salt or Solvate thereof.

15

or a pharmaceutically acceptable salt thereof.
12. A composition comprising a compound of claim 1 and
a pharmaceutical carrier, diluent, or excipient.
13. The composition of claim 12 wherein the composition
is formulated for intraperitoneal injection or infusion to a
mammal.

14. A composition comprising a compound of claim 11 and
a pharmaceutical carrier, diluent, or excipient.
15. The composition of claim 14 wherein the composition
is formulated for intraperitoneal injection or infusion to a

9. The compound of claim 1 wherein R and Rare (Co

Cs)alkyl, (Co-Cs)alkenyl, or (Co-Cs)alkanoyl groups.

mammal.

10. The compound of claim 9 wherein R and Rare tet

25

radecanoyl groups, tetradecanyl groups, or a combination
thereof.

16. A method for treating or inhibiting the deleterious
effects of endotoxemia comprising administering to a subject
afflicted with endotoxemia an effective amount of a compo
sition of claim 15 wherein the deleterious effects of endotox

emia are thereby treated or inhibited.
30

11. The compound of claim 1 wherein the compound is
19
35

O

OH, or
NHFmoc
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17. The method of claim 16 wherein the deleterious effects
of endotoxemia are one or more of a reduction in white blood

cells, a high respiratory rate, an elevated heart rate, an
elevated temperature, or multiple organ failure.
18. A method for blocking or inhibiting a signal transduc
tion pathway in gram-negative bacteria that leads to sepsis
comprising administering to a Subject afflicted with, or hav
ing an increased risk of being afflicted with, sepsis, an effec
tive amount of a composition of claim 15 wherein the signal
transduction pathway that leads to sepsis is blocked or inhib
ited.
19. A method to antagonize LPS signaling in gram-nega
tive bacteria that leads to sepsis comprising administering to
a subject afflicted with, or having an increased risk of being
afflicted with, sepsis, an effective amount of a composition of
claim 12 wherein LPS signaling is antagonized by the admin
istration of the composition.
k

k

k

k
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